СТЕРОИДНЫЕ САПОГЕНИНЫ И ИХ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ

... 1. Применение одного или нескольких активных агентов выбранных из группы, содержащей сарсасапогенин, смилаген, празеригенин, анзуроген-D, астрагалозид и неэстрогенный стероидный сапонин, иной, чем сапонин, обладающий способностью к инотропному действию на миокард, для приготовления композиции для лечения болезни Паркинсона человека. 2. Применение по п.1, где используют, по меньшей мере, два активных агента, определенных в п.1. 3. Применение по п.1, где активный агент включает сарсасапогенин. 4. Применение одного или нескольких активных агентов выбранных из группы, содержащей сарсасапогенин, смилаген, празеригенин, анзуроген-D, астрагалозид и неэстрогенный стероидный сапонин, иной, чем сапонин, обладающий способностью к инотропному действию на миокард, для приготовления композиции для лечения постуральной гипотензии, аутизма, синдрома хронической усталости, тяжелой миастении Грависа, болезни Ламберта Итона, синдрома войны в Заливе и синдрома, связанного с профессиональным контактом с фосфороорганическими ...

Ein Arzneimittel zur Behandlung von Gicht und dessen Herstellungsverfahren

Die vorliegende Erfindung offenbart ein Arzneimittel zur Behandlung von Gicht und dessen Herstellungsverfahren. Das Medikament zur Behandlung von Gicht umfasst nach Gewichtsteilen Lotus Plumule 5-15, Spina Date Seed 10-15, Houttuynia cordata 13-20, Angelica sinensis 12-28 und Herba Pyrolae 5-12. Das Arzneimittel zur Behandlung von Gicht gemäß der vorliegenden Erfindung weist im Vergleich zu den Arzneimitteln des Standes der Technik andere Bestandteile auf und kann die Mängel der Arzneimittel im Stand der Technik überwinden.

Herbal compositions

Compositions for use in preparing a potable decoction comprise coffee and one or more of the herbs: Hemidesmus indicus , Tinospora cordifolia and Withenia somnifera , and/or of extracts therefrom. Also disclosed are cosmetic compositions which comprise hydrolysed ghee and a decoction of the leaves of Jasminum grandiflorum .

Compositions having antiviral properties

Compositions having antiviral properties.

Compositions of the invention are elaborated from acetic acid and extracts of coconuts in powder, mineral salts solution, extracts of cactacea, liliaceous, anacardiaceae and euphorbiaceae.

Compositions having antiviral properties

Compositions having of the antiviral properties and proceeded of obtaining

Hydration compositions for human or animal bodies

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HERPES

The invention relates to a pharmaceutical composition for the treatment of herpes simplex virus infections, comprising a quaternary ammonium compound as a first component and/or an antiviral agent as a second component and/or a plant extract as a third component, wherein the three components are mutually compatible, in a pharmaceutically acceptable base.

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HERPES

The invention relates to a pharmaceutical composition for the treatment of herpes simplex virus infections, comprising a quaternary ammonium compound as a first component and/or an antiviral agent as a second component and/or a plant extract as a third component, wherein the three components are mutually compatible, in a pharmaceutically acceptable base.

Compositions having antiviral properties and preparation process

КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТИВИРУСНОЙ АКТИВНОСТЬЮ, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ

Изобретение относится к композиции, обладающей антивирусной активностью, полученной из уксусной кислоты и экстрактов из порошка кокосового ореха, раствора неорганических солей, экстрактов из кактусовых, лилейных, анакардиевых и молочайных. Изобретение относится также к способу получения указанной композиции и к фармацевтическому составу на основе этой композиции, используемой в качестве активного начала.

Traditional Chinese medicine formula for treating autologous allergic dermatitis and preparation method thereof

Traditional Chinese medicine enzyme for treating osteocarcinoma and preparation method thereof

Biological agent rapid to absorb and preparation method thereof

Medicinal liquor capable of activating blood circulation to dissipate stasis and relieving swelling and pain and application thereof

Health wine and preparation method thereof

Traditional Chinese medicine pill for treating gout

Plant-animal combined medicinal liquor for preventing and treating spleen deficiency and phlegm dampness type facial sores

Inflatable fumigating bed with convertible massage mode

IMMUNOSUPPRESSOR

PURPOSE: An immunosuppressor having a selective suppressor which has flavanoid or chromone as a reactive, against activated T cell is provided, which is useful for curing autoimmune diseases or inflammation caused by tissue damage or infection related with autoimmune diseases, fibrosis, malfunction, rejection of organ transplantation or bone marrow transplantation, allergy. CONSTITUTION: The formula 1 shows chemical structure of flavanoid or chromone, wherein, R is H or phenyl group substituted with one or two hydroxyl group; Rha is alpha-L-rhamnose group; and dotted line is double bond, is found which has enhanced activities of abnormal immune reaction. Flavonoid is extracted from Smilax glabra Roxb and purified or synthesized. Effective amount of flavonoid depends on the kind of disease, condition of patient, condition of disease, age, medication method, etc., and conventional daily dosage of flavonoid or chromone is 1-1000mg for oral use and 1/100-1/2 of the amount of oral use for non ...

USES OF ESMILAGENINA AND ANZUROGENINA D, PHARMACEUTICAL COMPOISÇÃO HAVING PROPERTIES INTENSIFIERS OF FUNCTION COGNITIVA, PROCESS TO INTENSIFY FUNCTION COGNITIVA, AND, COMPOSITION FOR USE OF THE SAME

TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING HAND-FOOT SYNDROME (HFS) AFTER TARGETED DRUG TREATMENT AND METHOD FOR MAKING THE SAME

A traditional Chinese medicine composition for treating hand-foot syndrome after targeted drug treatment is mainly prepared from the following components by weight: 20-50 parts of Radix Sophorae Flavescentis, 20-50 parts of Herba Taraxaci, 20-50 parts of Flos Chrysanthemi Indici, and 20-50 parts of Herba Cum Radice Violae Yedoensitis, 20-50 parts of Rhizoma Smilacis Glabrae, 30-60 parts of Radix Astragali Seu Hedysari, 10-35 parts of Kochia scoparia (L.) Schrad, 10-45 parts of Carthamus tinctorius L., 15-45 parts of Cortex Radicis Dictamni Dasycarpi, 5-15 parts of Herba Ephedrae, 5-25 parts of Angelica sinensis, 5-25 parts of Rhizoma Ligustici Chuangxiong, 10-30 parts of Radix Rehmanniae, 5-15 parts of Ramulus cinnamomi, 10-30 parts of Cynanchum otophyllum Schneid, 5-15 parts of Semen Sinapis Albae, 5-20 parts of Arisaema heterophyllum Blume, 5-20 parts of Typhonium blumei Nicolson & Sivadasan, and 10-40 parts of Radix Glycyrrhizae.

ГИДРАТИРУЮЩИЕ КОМПОЗИЦИИ ДЛЯ ОРГАНИЗМОВ ЧЕЛОВЕКА ИЛИ ЖИВОТНЫХ

Гидратирующая композиция для организма включает синергетическую комбинацию следующих компонентов: (a) Hydrastis canadensis (тривиальное название желтокорень канадский), (б) Ulmus fulva (тривиальное название вяз ржавый) и (в) Smilax ornata (тривиальное название сассапариль). Композиция может быть приготовлена в гомеопатической или негомеопатической форме. Гидратирующая композиция в гомеопатической форме может быть приготовлена любым из следующих методов. 1. Получение отдельных гомеопатических препаратов из компонентов (а, б и в) и их смешивание. 2. Смешивание экстрактов компонентов (а, б и в) и формирование из полученной смеси гомеопатической композиции. 3. Приготовление первой гомеопатической композиции, как в пунктах (1) и (2). Затем разбавление указанной первой композиции с образованием второй гомеопатической композиции. Изобретение позволяет усилить гидратацию организма и повысить поглощение кислорода на клеточном уровне. 11 с. и 5 з.п. ф-лы.

HYDRATATIONSZUSAMMENSETZUNGEN FÜR MENSCH ODER TIER

HERBAL CREAMS FOR PSORIASIS AND HERBAL COMPOSITION FOR CHRONIC SKIN DISORDERS

Membrane-bound receptors and their function; cognitive disfunction; treatments therefore; and compositions for use in such treatments

COMPOSITIONS WITH ANTIVIRAL EFFECTS AND PROCEDURES FOR THE PRODUCTION

HYDRATION COMPOSITIONS FOR HUMANS OR ANIMAL

CINNAMOMI AND PORIA COMPOSITION, PROCEDURE FOR THE PRODUCTION AND USES OF IT

SARSASAPOGENIN AND SMILAGENIN TO THE TREATMENT OF COGNITIVE DISTURBANCES

STEROIDALE SAPONINE FOR THE TREATMENT OF THE ALZHEIMERI ILLNESS

STEROIDAL SAPONINS FOR TREATING ALZHEIMER'S DISEASE

The invention discloses the use of a number of saponins and sapogenins, notably those of steroidal structure, in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are also disclosed.

Compositions having antiviral properties and preparation process

Kidney-tonifying and clearing mixture and preparation method thereof

Dual-specificity antibody

Combined traditional Chinese medicine preparation for treating diabetic foot and preparation method of preparation

Medicine for treating rheumatoid arthritis

Compositions based on arnica and their uses, in particular in pharmaceutical or cosmetic compositions

SMILAX ROOT COMPOSITION FOR PREVENTING AND IMPROVING OSTEOPOROSIS AND MANUFACTURING METHOD THEREOF

The present invention relates to a smilax root composition for preventing and improving osteoporosis and a manufacturing method thereof. The present invention is characterized in which it is possible to maximize an effect of preventing and/or improving osteoporosis through inhibition of osteoclast activity while minimizing side effects. The composition is composed of smilax root extract which is pharmaceutically effective using either water or aqueous solution of ethanol as an extraction solvent. COPYRIGHT KIPO 2018 (AA) Start (BB) End (S10) Roots of Cheongmyeongrae are naturally dried for 1 week to 3 weeks in a shady place away from direct sunlight. (S20) Sample is pulverized and mixed with the extraction solvent (S30) Sample is refluxed to extract the dried extract (S40) Dried extract is cooled to 15°C to 30°C and filtered to give a filtrate extract (S50) Filtrate is concentrated under reduced pressure to extract the root extract ...

A PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT OF SMILACIS GLABRAE RHIZOMA FOR PREVENTING, IMPROVING OR TREATING ACUTE PANCREATITIS

ANTIVIRAL AND RETROVIRAL COMPOSITION, IN PARTICULAR FOR TREATING AIDS

The invention relates to compositions having antiviral properties, in particular antiretroviral properties for treating AIDS. The invention also relates to a method for producing same. The compositions of the invention are characterized in that they are developed from acetic acid and coconut extracts, a solution of mineral salts, and extracts from the Cactaceae, Liliaceae, Anacardiaceae and Euphorbiaceae families.

SMILAGENIN AND ANZUROGENIN-D FOR THE TREATMENT OF ALZHEIMER'S DISEASE

L'invention concerne l'utilisation de smilagénine et d'anzurogénine D dans le traitement de dysfonctionnements cognitifs et d'affections similaires. Des méthodes de traitement et des compositions pharmaceutiques sont également décrites.

Therapeutic agents for respiratory diseases

TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING VARIOUS DISEASES AND PREPARATION METHOD THEREOF

The present invention relates to a traditional Chinese medicine composition for treating various diseases and a preparation method thereof. The traditional Chinese medicine composition for treating various diseases is prepared by using 39 traditional Chinese medicines including Glabrous greenbrier rhizome, Japanese honeysuckle stem, Cyathula officinalis Kuan, Corydalis bungeana, Radix Astragali, prepared common monkshood daughter root, Lalang grass rhizome, Rhizoma polygoni cuspidati, dried ginger, Polygonum aviculare, Liquorice root, Lobed kudzuvine root and Common selfheal spike and the like in proper weight ratio as the main raw materials. The resultant traditional Chinese medicine composition can be used to treat various related diseases including viral influenza, urinary tract infection, gynecological inflammation, hyperlipidemia, angiosclerosis, and the like. The traditional Chinese medicine composition can effectively play the effects of clearing heat and detoxicating, eliminating ...

The Compounds of Freeze Dried Powder of Cherry and Smilacis Glabrae Rhizoma and the Application in Preparation of Anti-gout Drugs thereof

Abstract The invention proposes the application of cherry lyophilized powder and its combination with smilacis glabrae rhizoma in preparing anti-gout medicine, and discloses the value of cherry lyophilized powder in Shiyan region of northwest Hubei province as anti-gout medicine. The cherry lyophilized powder is made from the cherry in Shiyan region of northwest Hubei province. The active ingredients of cherry is extracted by ultrasonic water method after core excision and the lyophilized powder is prepared by vacuum freeze-drying machine. The invention uses cherry lyophilized powder prepared from cherry in Shiyan area of northwest Hubei province as anti-gout drug, plays a role in reducing uric acid through non uric acid synthesis inhibition pathway, which has remarkable effect of reducing uric acid in mice with hyperuricemia, and is capable in reducing serum creatinine and urea nitrogen level in mice with hyperuricemia without obvious effect on kidney and liver.

SMILAGENIN AND ANZUROGENIN-D FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The invention discloses the use of a smilagenin and anzurogenin-D in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are also disclosed.

PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF ARTHRITIS

The pharmaceutical composition for treating arthritis comprises glucosamine or a salt thereof, plant materials or extracts, collagen, pantothenic acid and minerals. The minerals may be copper, manganese and selenium. The composition is made in a form for oral administration. The combination of the mineral components with the glucosamine and the plant materials produces a synergistic action in treating arthritis.

External plaster for rheumatic arthritis, and preparation method of external plaster

Medicine set box for psoriasis rehabilitation

External application vinegar for treating and preventing spleen deficiency and phlegm dampness type facial sores

Novel gout health tea extracted from pure Chinese herbal medicines

Traditional Chinese medicine patch for treating eczema and preparation method thereof

COMPOSITIONS HAVING OF the ANTIVIRAL PROPERTIES AND PROCEEDED Of OBTAINING

STIMULATION OF the SYNTHESIS OF the RECPTEURS MCR1, MCR2 AND µ OPIOIDE.

L'invention concerne des substances actives modulant l'expression des récepteurs des produits du gène POMC (MCR1, MCR2 et le récepteur µ opioïde), et éventuellement modulant l'expression de POMC, dans les cellules cutanées, notamment pour moduler la prolifération et la différenciation des cellules épidermiques, afin de ré-épitélialiser, de maintenir l'innervation, l'irrigation de la peau, ou de restaurer une pigmentation normale, ou pour lutter contre le vieillissement, ou pour moduler la pigmentation indépendamment ou non du vieillissement cutané. L'invention concerne également une méthode de criblage de tels principes actifs.

APPETIZING AND SUMMER HEAT RELIEVING TANGXIN RAW CIDER AND HIGH-EFFICIENCY DEEP PROCESSING TECHNOLOGY THEREOF

The disclosure relates to an appetizing and summer heat relieving tangxin raw cider and a high-efficiency deep processing technology thereof. The high-efficiency deep processing technology comprises the following steps: (1) preparing raw pulp; (2) detoxifying patulin; (3) inoculating and precisely fermenting; (4) performing enzymolysis of residues; (5) clarifying and filtering; (6) ageing; and (7) canning after adsorbing and clarifying. According to the disclosure, aiming at a phenomenon that cider is muddy after being stored, it is solved by adsorption with a multi-stimuli responsive nano fiber modified resin. Exterior stimuli include change in environment temperature or acidity-basicity (pH value), light, electric field, magnetic field or specific molecules. In response to exterior stimuli, nano fiber may include physicochemical properties such as size, hydrophilicity and hydrophobicity, refractive index, transmittance, mechanical strength, color or conductivity.

ALKALIZED ORGANIC PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION

The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

Pharmaceutical or nutraceutical composition

The invention relates to a pharmaceutical or nutraccutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance.

СТЕРОИДНЫЕ САПОГЕНИНЫ И ИХ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ

Изобретение относится к области медицины, а именно к фармакологии и психиатрии. Предложено использование сарсасапогенина, в случае необходимости с одним или несколькими соединениями из группы, состоящей из смилагена и анзурогенина-D, для приготовления композиции для лечения болезни Паркинсона или для лечения постуральной гипотензии, аутизма, синдрома хронической усталости, тяжелой миастении Грависа, болезни Ламберта Итона, синдрома войны в Заливе и синдрома, связанного с профессиональным контактом с фосфорорганичекими соединениями. Сарсасапогенин избирательно увеличивает активность мускариновых рецепторов M1, приводящих к усилению синаптической передачи, и не влияет на активность М2 рецепторов (которые вызывают отрицательную обратную связь и нарушают мускариновую передачу). 2 н. и 1 з.п. ф-лы, 8 табл.

Traditional Chinese medicine composition for treating hand-foot syndrome (HFS) after targeted drug treatment and method for making the same

Traditional Chinese medicine composition for treating hand-foot syndrome after targeted drug treatment comprising, by weight:20-50 parts of Radix Sophorae Flavescentis, 20-50 parts of Herba Taraxaci, 20-50 parts of Flos Chrysanthemi Indici, and 20-50 parts of Herba Cum Radice Violae Yedoensitis, 20-50 parts of Rhizoma Smilacis Glabrae, 30-60 parts of Radix Astragali Seu Hedysari, 10-35 parts of Kochia scoparia (L.) Schrad, 10-45 parts of Carthamus tinctorius L., 15-45 parts of Cortex Radicis Dictamni Dasycarpi, 5-15 parts of Herba Ephedrae, 5-25 parts of Angelica sinensis, 5-25 parts of Rhizoma Ligustici Chuangxiong, 10-30 parts of Radix Rehmanniae, 5-15 parts of Ramulus cinnamomi, 10-30 parts of Cynanchum otophyllum Schneid, 5-15 parts of Semen Sinapis Albae, 5-20 parts of Arisaema heterophyllum Blume, 5-20 parts of Typhonium blumei Nicolson & Sivadasan, and 10-40 parts of Radix Glycyrrhizae. Also claimed is a method for creating such a composition.

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HERPES

SMILAGENIN AND ANZUROGENIN D FOR THE TREATMENT OF THE ALZHEIMERI ILLNESS

Medicinal and edible health liquor and preparation method thereof

Traditional Chinese medicine ferment for treating gout and preparation method of traditional Chinese medicine ferment

Traditional Chinese medicine composition for treating lung cancer and preparation method thereof

Traditional Chinese medicinal composition for treating lipomas as well as preparation method and application thereof

Radix codonopsis and radix astragali liver disease treating tablet

Traditional Chinese medicine for treating diabetic acromegaly necrosis

Traditional Chinese medicine for treating psoriasis

INHIBITION OF AGE FORMATION

The present invention relates to the use of an active substance that promotes the inhibition of AGE formation, for the preparation of a composition for preventing and/or combating the decrease in elastic and plastic properties of tissues, and in particular of the skin, for inhibiting AGE formation, or for preventing and/or combating protein glycation at the cutaneous level. The invention also relates to a method of screening for such active substances. COPYRIGHT KIPO & WIPO 2010 ...

EXTRACT OF SMILAX CHINA ROOT HAVING ESTROGEN-LIKE EFFECT

The present invention relates to an extract of Smilax china root having an estrogen-like effect, and specifically, to a composition for preventing, treating, or ameliorating a disease caused by an estrogen deficiency containing an extract of Smilax china roots as an active ingredient. The compositions of the present invention originally can bind to estrogen receptors α and β, such as estrogen, to activate signaling mechanisms derived from the bond of estrogen and estrogen receptors; and can promote the proliferation of breast cells in which the estrogen receptors are expressed. Therefore, the composition of the present invention can effectively prevent, treat or ameliorate a disease caused by estrogen deficiency. COPYRIGHT KIPO 2018 (A) Estrogen receptor α binding activity (B) Estrogen receptor β binding activity ...

HYDRATATIONSZUSAMMENSETZUNGEN FÜR MENSCH ODER TIER

TRADITIONAL CHINESE MEDICINE COMPOSITION, TRADITIONAL CHINESE MEDICINE COMPOUND PREPARATION FOR TREATING GOUT AND PREPARATION METHOD THEREOF

The present invention discloses a traditional Chinese medicine composition, a traditional Chinese medicine compound preparation for treating gout and a preparation method thereof. It takes traditional Chinese medicine sunflower head, rhizoma smilacis glabrae and coix seed as s main components with sunflower head as the monarch drug, and rhizoma smilacis glabrae and coix seed as assistant and guide drugs, and cures both symptoms and root causes, achieving the purpose of treating gout, rheumatoid arthritis and other arthritis, mainly based on regulating and nourishing the spleen, liver and kidney, supporting the healthy energy, and supplemented by dispelling damp heat. The present invention not only has good anti-inflammatory effect and 10 uric acid lowering effect, but also has good protection effect on liver and kidney, especially is significantly different from the clinically commonly used chemical drug allopurinol in terms of protecting the liver and kidney, showing a unique clinical ...

Compositions having antiviral properties and preparation process

DRINKING TEA FOR TREATING DERMATITIS

Technical Field: Tea. Technical Problem: To provide drinking tea showing favorable therapeutic effects on atopic dermatitis. Means for Resolution: Drinking tea characterized by containing one or more plant extracts selected from the group consisting of Sophorae Radix, Baphicacanthes cusia and myrobalan. Owing to the antibacterial and antiviral effects of Sophorae Radix, Baphicacanthes cusia and myrobalan, antiallergic effect ofSophorae Radix and Baphicacanthes cusia, intestinal mucosa-protecting effect of myrobalan or synergistic effects thereof, allergic soma can be ameliorated from the inside of the body and thus atopic dermatitis can be treated. Moreover, one or more auxiliaries selected from the group consisting of Angelicae Radix, Oldenlandia diffusa, Hoelen, citrus unshu peel, Flos chrysanthemi Indi, Corydalis Tuber, Menthae Herba, Scutellariae Radix, Lithosperni Radix, Ku Dung Cha, Polygonum cuspidantum and Glycyrrhizae Radix may be added to the above-described plant extracts so ...

COMPOSITIONS HAVING ANTIVIRAL PROPERTIES AND PREPARATION PROCESS

Les compositions de l'invention sont élaborées à partir d'acide acétique et d'extraits de poudre de noix de coco, de solution de sels minéraux, d'extrai ts de cactacée, de liliacée, d'anacardiacée, et d'euphorbiacée.

Traditional Chinese medicine antibacterial spray and its preparation and use

Medicine for treating ascariasis

Blood circulation activating health care wine and preparation method thereof

Radix Angelicae Sinensis and Radix Glycyrrhizae decoction

USE OF ACTIVE INGREDIENTS STIMULATING THE HUMAN BETA-DEFENSINES OF TYPE 2 AND/OR TYPE 3

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HERPES

The invention relates to a pharmaceutical composition for the treatment of herpes simplex virus infections, comprising a quaternary ammonium compound as a first component and/or an antiviral agent as a second component and/or a plant extract as a third component, wherein the three components are mutually compatible, in a pharmaceutically acceptable base.

Herbal Compositions

Natural plant feed additive for poultry

The invention provides a plant feed additive, which consists of main medicines and optional auxiliary materials, and is characterized in that the main medicines include the following basic components in parts by weight: 15-35 parts of pine needles, 10-35 parts of turmeric, 5-15 parts of glabrous greenbrier rhizome, 10-40 parts of spatholobus stem, 5-15 parts of pericarpium citri reticulatae, 5-20 parts of eucommia leaves and 5-15 parts of sweet wormwood. The feed additive disclosed by the invention has the effects of preventing or treating enteritis of poultry (chicken, duck, goose or quail and the like), improving poultry production performance or improving egg quality.

Medicine for treating tinea of feet and hands and preparation method thereof

Fresh rhizoma smilacis glabrae extract freeze-dried powder decoction piece

SUBSTANCES INHIBITING THE GLYCATION OF PROTEINS.

Non-irritating topical cosmetic or pharmaceutical bactericidal and/or fungicidal compositions, e.g. for acne or dermatitis treatment, containing human beta-defensin type 2 and/or 3 expression stimulants

L'invention concerne des principes actifs capables de stimuler l'expression, directe ou indirecte, des bêta-défensines humaines de type 2 et/ou bêta-défensines humaines de type 3. Ainsi l'invention fournit un principe actif capable de stimuler l'expression, directe ou indirecte, des bêta-défensines humaines de type 2 et/ou bêta-défensines humaines de type 3 caractérisé en ce que ledit principe actif n'entraîne pas de réactions inflammatoire(s), d'irritation(s) ou d'intolérance(s). L'invention fournit aussi une méthode de criblage permettant de sélectionner de tels principes actifs L'invention trouve l'application dans la préparation de composition cosmétique ou pharmaceutique contenant de tels principes actifs.

Alzheimer hastalığının tedavisi için steroit sapogenler ve bunların türevleri

Creams useful for treating psoriasis,exzema and lichen planus

Topical applied creams for alleviating chronic skin disorders comprise mixtures of hydrolysed Ghee (butterfat) and extracts from Trifla, Terminalia chebula and belerica, Phyllanthus embelica, Melia azadirecta and Tenospora cordifolia.

Herbal Compositions

Smilagenin and anzurogenin-d and their use

COMPOSITIONS HAVING ANTIVIRAL PROPERTIES AND PREPARATION PROCESS

Les compositions de l'invention sont élaborées à partir d'acide acétique et d'extraits de poudre de noix de coco, de solution de sels minéraux, d'extraits de cactacée, de liliacée, d'anacardiacée, et d'euphorbiacée.

IMMUNOSUPPRESIVE AGENTS

An immunosuppressive agent which is very effective for treating autoimmune disease, inflammatory reaction, fibrosis or dysfunction caused by autoimmune disease and related disease thereof with tissue injury or infection, rejection of transplantation, graft versus host disease by bone marrow (hematopoietic stem cell) transplantation,or allergic disease, by selectively inhibiting the activated T cells, is provided.

SYNERGESTIC COMBINATION COMPOSITION COMPRISING A STEROIDAL SAPONIN, A FIRST POLYPHENOLIC COMPOUND AND A SECOND POLYPHENOLIC COMPOUND

A combination composition comprising as active components, in synergistically effective amounts of (i) a steroidal saponin of natural or synthetic origin, a pharmaceutical acceptable salt thereof or a plant extract containing steroidal saponin, and (ii) at least a first polyphenolic compound selected from the group consisting of hydroxycinnamic acids, flavonoids, hydroxybenzoic acids, and (iii) optionally, a second polyphenolic compound, wherein the second polyphenolic compound is hydroxycinnamic acids and its use in preventing, inhibiting, retarding or treating a subject suffering from a neurodegenerative disease or condition.

Formulation for Prevention and Treatment of Bacterial Infections and Preparation Thereof

The invention provides a formulation for the prevention and treatment of bacterial infections by administering an effective amount of the formulation comprising an extract of at least one plant selected from Allium sativum, Acorus calamus, Alstonia scholaris, Carissa spinarum, Cissampelos pareria, Chenopodium ambrosioides, Moringa olifera, Paederia foetida, Shorea robusta, Piper nigrum, Pueraria tuberosa, Ocimum sanctum, Terminalia bellirica, Tinospora cordifolia and Zingiber officinale , and a combination thereof. The invention also provides a process for preparing and method of using the same.

Compositions and Methods for Treatment and Management of Pain

Disclosed herein are compositions and methods for the treatment and management of pain in a subject, comprising topically or orally administering a therapeutically effective amount of a composition comprising herbal extracts and compound mixtures to a subject. The composition includes turmeric extract, Boswellia extract, ginger extract, holy basil extract, rosemary extract, white willow extract and alpha lipolic acid

Skin care products and compositions

Disclosed herein is a composition for treating maladies in humans or animals that includes from about 0.01% to about 40% by weight of a member of the curcuma genus, from about 0.01% to about 40% by weight of a member of the coffea genus and the balance being a pharmaceutically acceptable carrier.

Nutritional supplement

A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1., from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.

Chinese herbal medicine composition used for antiinflammation, detumescence and acesodyne, and preparation method and use thereof

A Chinese herbal medicine composition used for antiinflammation, detumescence and acesodyne, comprising first type of medicinal materials and second type of medicinal materials. The first type of medicinal materials include Rhizoma Bletillae, Cortex Cinnamomi, Radix Angelicae Formosanae, Radix Angelicae Sinensis, Paeonia Lactiflora, Rhizoma Notopterygii, Radix Linderae, Glycyrrhizae, Radix Angelicae Pubescentis, and Radix Et Rhizoma Rhei. The second type of medicinal materials is one, two or three selected from the group cosisting of Zingiber Officinale, Olibanum and Myrrha. The preparation method for the Chinese herbal medicine composition comprises the following steps: adding the first type of medicinal materials and the second type of medicinal materials into a container with organic solvent, heating, filtering, and then condensing the filtrate into an extratum.

Herbal extracts and flavor systems for oral products and methods of making the same

The invention provides a method for preparing an herbal extract and a flavor system comprising an herbal extract produced by the process. The invention also provides a flavor system comprising an herbal extract comprising thymol, eugenol, carvacrol and eucalyptol. The invention further provides a flavor system comprising a thyme extract having a minimum inhibitory concentration of less than about 3%. Additionally, the invention provides an oral product comprising a flavor system.

Method of assisting with digestive upsets using a confection-based delivery of peppermint oil and ginger

A confection for assisting with the relief of common digestive complaints is provided. The confection includes a carbohydrate base and an active agent infused into the carbohydrate base. The active agent includes at least one of ginger extract or peppermint oil.

Composition for improving blood circulation, containing extract of lindera obtusiloba as active ingredient

Provided is a composition for improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient, and more specifically, to a pharmaceutical composition and a health functional food for preventing and treating thrombotic disorders by improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient. The extract of Lindera obtusiloba of the present invention and a crude purified product thereof can be obtained through extraction using various solvents such as water, ethanol, methanol, butanol, etc. Since the extract and the crude purified product have not only excellent inhibitory effect on platelet aggregation induced by various aggregation inductions in vitro, but also excellent inhibitory effect on rapid thrombus formation in vivo, they can be useful for preventing and treating diseases caused by blood circulation disorders such as thromboembolism, etc.

Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells

The present invention relates to herbal medicinal compositions and extracts thereof for inhibiting growth of cancer cells. One of the examples described in the present invention comprises Forsythiae fructus, Menthae Herba, Gardeniae Fructus, Scutellariae Radix, Lophatheri Folium, Glycyrrhizae Radix, Rhei Rhizoma, Na 2 SO 4 , and Atractylodis Rhizoma. The residual examples are described herein.

Composition and method to alleviate joint pain

Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.

Ginger Extract for Inhibiting the Fat-storage Function of Adipocytes and a Medication thereof

In the present invention, a ginger extract for inhibiting the fat-storage function of adipocytes and a medication thereof is disclosed, wherein the ginger extract is obtained form Alpinia galangal and Zingiber zerumbet.

Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like loxl for stimulating the formation of elastic fibers

The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells

The present invention relates to herbal medicinal compositions and extracts thereof for inhibiting growth of cancer cells. One of the examples described in the present invention comprises Forsythiae fructus, Menthae Herba, Gardeniae Fructus, Scutellariae Radix, Lophatheri Folium, Glycyrrhizae Radix, Rhei Rhizoma, Na 2 SO 4 , and Atractylodis Rhizoma. The residual examples are described herein.

Warming Inch Loss Delivery System

This invention is a topical treatment for the skin, used for skin enhancement, firming, smoothing, refining and to reduce the appearance of cellulite; that has a self-warming or thermogenic effect comprised of a base combination of warming herbs (Ayurvedic), being any herbs that create a warming effect, combined with dietary minerals that can be blended together in any ratio.

PHARMACEUTICAL COMPOSITION

A method of treating a respiratory disease in an animal comprising the steps of administering to the animal an effective amount of a pharmaceutical composition comprising 1.5 parts by weight powdered fennel, 2.0 parts by weight powdered rhubarb, 1.0 part by weight powdered glycyrrhiza, 2.0 parts by weight powdered phellodendron bark, 1.0 part by weight powdered zedoary, 1.5 parts by weight powdered picrasma wood, 1.0 part by weight powdered matricaria chamomilla, 1.5 parts by weight powdered geranium herb, 1.0 part by weight powdered ginseng, 1.5 parts by weight powdered citrus unshiu peel, 1.0 part by weight powdered scutellaria root, 1.0 part by weight powdered magnolia bark, 2.0 parts by weight powdered oyster shell, 1.0 part by weight powdered cyperus rhizome, 2.0 parts by weight powdered platycodon root, 2.0 parts by weight powdered melia azedarach, 1.0 part by weight powdered cnidium rhizome, 2.0 parts by weight sodium bicarbonate and 4.0 parts by weight precipitated calcium carbonate in 30 parts by weight of the composition. 1. A method of treating a respiratory disease in an animal comprising the steps of administering to the animal an effective amount of a pharmaceutical composition comprising:1.5 parts by weight powdered fennel;2.0 parts by weight powdered rhubarb;1.0 part by weight powdered glycyrrhiza;2.0 parts by weight powdered phellodendron bark;1.0 part by weight powdered zedoary;1.5 parts by weight powdered picrasma wood;1.0 part by weight powdered matricaria chamomilla;1.5 parts by weight powdered geranium herb;1.0 part by weight powdered ginseng;1.5 parts by weight powdered citrus unshiu peel;1.0 part by weight powdered scutellaria root;1.0 part by weight powdered magnolia bark;2.0 parts by weight powdered oyster shell;1.0 part by weight powdered cyperus rhizome;2.0 parts by weight powdered platycodon root;2.0 parts by weight powdered melia azedarach;1.0 part by weight powdered enidium rhizome;2.0 parts by weight sodium bicarbonate; and4.0 parts ...

Compositions comprising lipophilic extracts of zingiber officinale and echinacea angustifolia for the prevention and treatment of gastro-oesophageal reflux and chemotherapy-induced emesis

The present invention relates to compositions consisting of a combination of lipophilic extracts of Zingiber officinale and Echinacea angustifolia , obtained by extraction with carbon dioxide under supercritical conditions, which are useful for the prevention and treatment of oesophageal reflux and chemotherapy-induced emesis.

COMPOSITIONS FOR THE SYMPTOMATIC RELIEF OF STOMACH PAIN OR GASTROOESOPHAGEAL REFLUX

Compositions useful for relieving the symptoms commonly known as stomach acidity, heartburn or, more technically, esophageal reflux (GERD), that comprise a fatty acid and a plant extract. These compositions have been tried in patients with clinical records of previous diagnosis of GERD, chronic heartburn, or esophagitis, with a high degree of success. 2. The composition of claim 1 , wherein the plant extract from the alliaceae family is a garlic extract.3. The composition of claim 2 , wherein the garlic extract is powdered claim 2 , non-deodorized claim 2 , dry extract.4. The composition of claim 1 , wherein the alkali or alkaline-earth metal salt of at the least one C1-C10 fatty acid is a sodium claim 1 , calcium or potassium salt thereof.5. The composition of claim 4 , wherein the sodium claim 4 , calcium or potassium salt of the C1-C10 fatty acid is sodium butynate.6. The composition of claim 4 , wherein the sodium claim 4 , calcium or potassium salt of the C1-C10 fatty acid is buffered with a buffer selected front phosphate salts and carbonate salts.7. The composition of claim 1 , wherein the glycerol ester of at least one C1-C10 fatty acid is a triglyceride thereof.8. The composition of claim 1 , further comprising a curcuma plant extract.9. The composition of claim 1 , further comprising at least one excipient selected from the group consisting of vehiculizing agents claim 1 , thinners claim 1 , disintegrants claim 1 , lubricants claim 1 , binders claim 1 , gellants claim 1 , flavors claim 1 , sweeteners claim 1 , coloring agents claim 1 , preservatives claim 1 , fillers claim 1 , antioxidants claim 1 , encapsulating coadjuvants and coating agents.10. The composition of claim 1 , which is presented in the form of capsule claim 1 , pill claim 1 , sachet claim 1 , tablet or coated tablet.11. The composition of claim 1 , for the re-establishment of digestive homeostasis affected by peptic-acid disorders and/or states of disorder caused by damage to the gastric ...

Ginger Extract for Inhibiting the Fat-Storage Function of Adipocytes and a Medication Thereof

In the present invention, a ginger extract for inhibiting the fat-store function of adipocytes and a medication thereof is disclosed, wherein the ginger extract is obtained form and In the present invention, said ginger extract is further administrated to a target in need for inhibiting fat-storage function of adipocytes in the target. 1. A method of inhibiting fat-storage function of adipocytes , said method comprising:administrating an effective amount of a ginger extract to a target in need thereof, wherein the ginger extract is obtained by a process comprising:{'i': Alpinia galanga', 'Zingiber zerumbet,', 'Alpinia galanga', 'Zingiber zerumbet', 'Alpinia galanga', 'Zingiber zerumbet', 'Alpinia galanga', 'Zingiber zerumbet;, 'providing roots or stems of and followed by drying the roots or stems of and till water contents of the roots or stems of and being lower than 10%, to obtain a dry and a dry'}{'i': Alpinia galanga', 'Zingiber zerumbet, 'preparing a ginger component by mixing the dry and the dry in a weight ratio of 1:3 to 3:1 and then extracting the ginger component with a solvent to obtain a liquid extract; and'}condensing the liquid extract.2. The method of inhibiting the fat-storage function of adipocytes as defined in claim 1 , wherein the solvent is selected from one of water claim 1 , methanol ethanol acetone claim 1 , ethane claim 1 , propane claim 1 , butane and hexane.3. The method of inhibiting the fat-storage function of adipocytes as defined in claim 1 , wherein the extracting comprises extracting the ginger component with the solvent in a weight ratio of 1:8 to 1:12.4. The method of inhibiting the fat-storage function of adipocytes as defined in claim 1 , wherein the extracting is processed via sonication.5. The method of inhibiting the fat-storage function of adipocytes as defined in claim 1 , wherein the drying is processed via lyophilization claim 1 , spray drying claim 1 , evaporation or heating drying.6. The method of inhibiting the fat- ...

COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOF

Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient. 1. A composition comprising a mixture of plant extracts , wherein the mixture comprises:a) at least one Group I plant extract and at least one Group II plant extract, wherein the at least one Group I plant extract and the at least one Group II plant extract are different;b) at least one Group I plant extract and at least one Group III plant extract, wherein the at least one Group I plant extract and the at least one Group III plant extract are different;c) at least one Group I plant extract and at least one Group IV plant extracts, wherein the at least one Group I plant extract and the at least one Group IV plant extract are different;d) at least one Group II plant extract and at least one Group III plant extracts, wherein the at least one Group II plant extract and the at least one Group III plant extract are different;e) at least one Group II plant extract and at least one Group IV plant extract, wherein the at least one Group II plant extract and the at least one Group IV plant extract are different;f) at least one Group III plant extract and at least one Group IV plant extract, wherein the at least one Group III plant extract and the at least one Group IV plant extract are different;g) at least one Group I plant extract, at least one Group II plant extract, and at least one Group III plant extract, wherein the at least one Group I plant extract, the at least one Group II plant extract, and the at least one Group III plant extract are different;h) at least one Group I plant extract, at least one Group II plant extract, and at least one Group IV plant extract, wherein the at least one Group I plant extract, the at least one Group II plant extract, and the at least one Group IV plant extract are different;i) at least one Group I plant extract, at ...

Composition for Reducing Side- and After-Effects of Cancer Treatment

A compound for consumption by cancer patients, or others currently suffering from side effects such as those commonly associated with chemotherapy, that supplies herbal tonics with certain properties believed to ameliorate many of the side effects discussed above, and which has taste masking properties that improve the patient's tolerance of the supplement and likelihood to consistently consume the supplement. The compound is a mixture generally containing three core components: whey protein, which has a number of significant health benefits for cancer patients; hepatoprotectant and/or nephroprotectant agents(s), which reduce damage to the kidneys and liver; and anti-emetic agent(s), which reduce nausea and vomiting. 1. A liquid composition comprising:whey protein;an anti-emetic; anda hepatoprotectant.2. The composition of wherein said anti-emetic provides the resultant taste profile of said composition.3. The composition of wherein said anti-emetic comprises ginger.4. The composition of wherein said hepaprotectant comprises milk thistle.5. The composition of further comprising a taste masking agent.6. The composition of wherein said taste masking agent comprises miraculin7. The composition of wherein the taste masking agent comprises a flavouring.8. A liquid composition consisting essentially of:whey protein;an anti-emetic; anda hepatoprotectant.9. The composition of wherein said anti-emetic provides the resultant taste profile of said composition.10. The composition of wherein said anti-emetic is selected from the group consisting of: ginger and peppermint.11. The composition of wherein said hepaprotectant is milk thistle.12. A method of treating the side effects of cancer treatment comprising administering a liquid composition comprising the following:whey protein;an anti-emetic; anda hepatoprotectant.13. The method of wherein said liquid composition is administered prior to a treatment being administered.14. The method of wherein said anti-emetic provides the ...

Treatment of Neurocutaneous Syndrome, Including Compositions, Methods and Uses Thereof

A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.

Treatment of Neurocutaneous Syndrome, Including Compositions, Methods and Uses Thereof

A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.

TIE2 Activator, Vascular Endothelial Growth Factor (VEGF) Inhibitor, Angiogenesis Inhibitor, Vascular Maturing Agent, Vascular Normalizing Agent and Vascular Stabilizing Agent, and Pharmaceutical Composition

A Tie2 activator containing, as an active ingredient, a hawthorn extract, a starfruit extract, a shellflower extract, a lotus extract, a rooibos extract, an Indian date extract, a Chinese quince extract, a Psidium guava extract, a long pepper extract, a Quillaja extract, a Kouki extract, a ginkgo extract, an oyster extract, a turmeric extract, a chrysanthemum extract, a jujube extract, a Chinese wolfberry extract, a chamomile extract, or a Butcher's Broom extract, or any combination thereof. 1. A Tie2 activator comprising , as an active ingredient , a hawthorn extract , a starfruit extract , a shellflower extract , a lotus extract , a rooibos extract , an Indian date extract , a Chinese quince extract , a Psidium guava extract , a long pepper extract , a Quillaja extract , a Kouki extract , a ginkgo extract , an oyster extract , a turmeric extract , a chrysanthemum extract , a jujube extract , a Chinese wolfberry extract , a chamomile extract , or a Butcher's Broom extract , or any combination thereof.2. An angiogenesis inhibitor comprising , as an active ingredient , a hawthorn extract , a starfruit extract , a shellflower extract , a lotus extract , a rooibos extract , an Indian date extract , a Chinese quince extract , a Psidium guava extract , a long pepper extract , a Quillaja extract , a Kouki extract , a ginkgo extract , an oyster extract , a turmeric extract , a chrysanthemum extract , a jujube extract , a Chinese wolfberry extract , a chamomile extract , or a Butcher's Broom extract , or any combination thereof.3. A vascular maturing agent comprising , as an active ingredient , a hawthorn extract , a starfruit extract , a shellflower extract , a lotus extract , a rooibos extract , an Indian date extract , a Chinese quince extract , a Psidium guava extract , a long pepper extract , a Quillaja extract , a Kouki extract , a ginkgo extract , an oyster extract , a turmeric extract , a chrysanthemum extract , a jujube extract , a Chinese wolfberry extract , a ...

Formulations containing extracts of echinacea angustifolia and zingiber officinale which are useful in reducing inflammation and peripheral pain

Disclosed is a combination of lipophilic extracts of Zingiber officinale and Echinacea angustifolia for the treatment of itching, peripheral pain, superficial and deep inflammatory and painful states, pain associated with muscle spasms, herpes pain, and radiodermatitis caused by oncological radiotherapy, with or without fungal or bacterial infections.

COMPOSITIONS AND METHODS FOR TREATMENT AND MANAGEMENT OF PAIN

Disclosed herein are compositions and methods for the treatment and management of pain in a subject comprising or consisting of topically or orally administering a therapeutic effective amount of a composition. The composition is made up of minute amounts of herbal extracts and compound mixtures to a subject. The composition includes turmeric extract, extract, ginger extract, holy basil extract, rosemary extract, white willow extract and alpha lipolic acid each in minute amounts. 1Boswellia. An herbal composition for the management of pain comprising turmeric extract , extract , ginger extract , holy basil extract , rosemary extract , willow bark extract and alpha lipolic acid and wherein each of said extracts and said alpha lipolic acid include an amount of active ingredients of between 0.00015% by wgt. and 0.01% by wgt.2Boswellia. The herbal composition for the management of pain according to claim 1 , which includes turmeric extract in an amount of between 0.00864% by wgt. and 0.01966% by wgt. claim 1 , extract in an amount of between 0.0063% by wgt. and 0.0077% by wgt. claim 1 , ginger extract in an amount of between 0.00045% by wgt. and 0.00055% by wgt. claim 1 , holy basil extract in an amount of between 0.00018% by wgt. and 0.00022% by wgt. claim 1 , rosemary extract in an amount of between 0.00054% by wgt. and 0.00066% by wgt. claim 1 , willow bark extract in an amount between 0.00135% by wgt. and 0.00165% by wgt. and alpha lipolic acid in an amount between 0.009% by wgt. and 0.011% by wgt.3Boswellia. The herbal composition for the management of pain according to claim 2 , which includes turmeric extract in an amount of about 0.0096% by wgt. claim 2 , extract in an amount of about 0.007% by wgt. claim 2 , ginger extract in an amount of about 0.0005% by wgt. claim 2 , holy basil extract in an amount of about 0.0002% by wgt. claim 2 , rosemary extract in an amount of about 0.0006% by wgt. claim 2 , willow bark extract in an amount of about 0.0015% by wgt. and ...

Epidermal Growth Factor Composition, A Process Therefor and Its Application

A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant. 1. A composition comprising recombinant human epidermal growth factor present in a range of about 0.001% to about 0.9% (w/w); L-lysine hydrochloric acid present in the range of about 0.2% to about 0.5% (w/w) and mannitol present in the range of about 1% to about 10% (w/w) as stabilizers; sodium methyl paraben present in the range of about 0.016% to about 0.18% (w/w) and sodium propyl paraben present in the range of about 0.01% to about 0.02% (w/w) as preservatives; poly acrylic acid present in the range of about 0.25% to about 1% (w/w) as a thickening agent; water present in the range of about 50% to about 99.5% (w/v) as a carrier; triethanol amine present in an effective amount to maintain the pH of the composition between 6.3 to 6.4 as a pH regulating agent; glycerol present in the range of about 1% to about 2.5% (w/w) as a humectant; and a therapeutic agent present in a range of about 0.005% to about 0.5% (w/w).2. The composition of claim 1 , wherein the recombinant human epidermal growth factor is in a topical formulation in the form of gel claim 1 , spray claim 1 , ointment claim 1 , cream and lotion claim 1 , in oral formulation in the form of tablet and capsule claim 1 , or in parenteral formulation in the form of injections.3. The composition of claim 1 , wherein the therapeutic agent is an antiinfective agent silver sulphadiazine present in a range of about 0.005% to about 0.5% (w/w).4. The composition of claim 1 , wherein the therapeutic agent is a recombinant antibiotic lysostaphin present in the range of about 0.01% to about 0.1% (w/w).5. The composition of claim 1 , wherein the therapeutic agent ...

Composition and method to alleviate joint pain

Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.

COMPOSITION FOR PREVENTING OR TREATING LIVER TOXICITY COMPRISING GALGEUNTANG OR LACTIC ACID BACTERIA FERMENTED GALGEUNTANG

The present invention relates to lactic acid fermented Galgeuntang, and a composition comprising the said lactic acid bacteria fermented Galgeuntang or Galgeuntang as an active ingredient, more particularly, to lactic acid fermented Galgeuntang prepared by the steps of inoculating lactic acid bacteria to Galgeuntang, culturing thereof, and fermenting thereof, and a composition for preventing or treating liver toxicity comprising the said fermented Galgeuntang or Galgeuntang. The composition of the present invention has treatment effect on liver toxicity, so that it can be effectively used as a liver function recovering agent or health food for liver function recovery. 113-. (canceled)14. A method for prevention or treatment of liver toxicity comprising the step of administrating a composition comprising either or both of Galgeuntang and lactic acid bacteria fermented Galgeuntang as an active ingredient.15Puerariae radixCinnamomi ramulus. The method according to claim 14 , wherein the Galgeuntang is prepared by hot water extraction of the mixture of medicinal herbs including Galgeun () claim 14 , mahuang claim 14 , ginger claim 14 , jujube claim 14 , licorice claim 14 , peony and gyeji ().16Cinnamomi ramulusPuerariae radix. The method according to claim 14 , wherein the Galgeuntang is prepared by mixing 2-10 parts by weight of mahuang claim 14 , 2-10 parts by weight of ginger claim 14 , 2-10 parts by weight of jujube claim 14 , 1-7 parts by weight of licorice claim 14 , 1-7 parts by weight of peony claim 14 , and 1-7 parts by weight of gyeji () with 12 parts by weight of Galgeun ().17. The method according to claim 14 , wherein the lactic acid bacteria fermented Galgeuntang is prepared by fermenting the Galgeuntang inoculated with lactic acid bacteria.18Bifidobacterium, Lactobacillus, Streptococcus, Leuconostoc, PediococcusLactococcus. The method according to claim 14 , wherein the lactic acid bacteria are selected from the group consisting of claim 14 , and sp. ...

NOVEL HERBAL COMPOSITION FOR THE TREATMENT OF WOUND HEALING, A REGENERATIVE MEDICINE

The present invention discloses a novel, synergistic, effective herbal composition as a regenerative medicine comprising combination therapeutically effective amounts of extracts obtained from and , along with optionally comprising Pig fat in (Til) oil as a base, useful for the treatment of wound healing. The present invention also discloses a process for preparation of said herbal composition. 1. A novel , synergistic , effective herbal composition as a regenerative medicine for the treatment of wound healing comprising ,{'i': 'Curcuma longa', 'extracts of in an amount of about 5 to 15%;'}{'i': 'Glycyrrhiza glabara', 'extracts of in an amount of about 2 to 30%;'}{'i': 'Hamiltonia suaveolens', 'extracts of in an amount of about 2 to 50%;'}{'i': 'Typha angustifolia', 'extracts of in an amount of about 1 to 50%; and'}{'i': 'Azadirachta indica', 'extracts of in an amount of about 0.5 to 30% of the total composition.'}2Sesamum indicum. The herbal composition as claimed in claim 1 , wherein said composition further comprises oil as a base.3Sesamum indicum. The herbal composition as claimed in claim 2 , wherein oil is present in an amount of about 20 to 60% of the total composition.4. The herbal composition as claimed in claim 3 , wherein said composition comprises claim 3 ,{'i': 'Curcuma longa', 'extracts of in an amount of about 7 to 13%;'}{'i': 'Glycyrrhiza glabara', 'extracts of in an amount of about 5 to 20%;'}{'i': 'Hamiltonia suaveolens', 'extracts of in an amount of about 5 to 30%;'}{'i': 'Typha angustifolia', 'extracts of in an amount of about 2 to 40%;'}{'i': 'Azadirachta indica', 'extracts of in an amount of about 1 to 25% and'}{'i': 'Sesamum indicum', 'oil as a base in an amount of about 25 to 55% of the total composition.'}5. The herbal composition as claimed in claim 3 , wherein said composition comprises claim 3 ,{'i': 'Curcuma longa', 'extracts of in an amount of about 10 to 12%;'}{'i': 'Glycyrrhiza glabara', 'extracts of in an amount of about 8 to 15 ...

METHODS FOR TREATING NEUROLOGICAL DISORDERS USING NUTRIENT COMPOSITIONS

Nutrient compositions comprising botanical extracts and methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one or more symptoms thereof are also disclosed. 154-. (canceled)55gymnema sylvestre, commiphora mukul, curcuma longa, camellia sinensis, emblica officinalisterminalis chebula.. A method for treating apraxia , autism , speech impairments , traumatic brain injury , seizure disorders , epilepsy , global delays , or ADHD , comprising administering to a patient in need thereof a nutrient composition that ameliorates one or more symptoms of apraxia , autism , speech impairments , traumatic brain injury , seizure disorders , epilepsy , global delays , or ADHD , said nutrient composition comprising an effective amount of a mixture or purified mixture thereof comprising three or more botanical extracts selected from the group of botanicals consisting of , and56. A method according to claim 55 , wherein the nutrient composition is in granular or powder form.57. A method according to claim 56 , wherein the nutrient composition is capable of being administered orally.58. A method according to claim 57 , wherein the nutrient composition is combined with a liquid vehicle for oral consumption by the patient.59. A method according to claim 58 , wherein the liquid vehicle comprises water or milk.60gymnema sylvestre, commiphora mukul, curcuma longa, camellia sinensis, emblica officinalisterminalis chebula,. A method according to claim 55 , wherein the nutrient composition comprises a mixture or purified mixture thereof comprising botanical extracts selected from each of claim 55 , and61cinnamomum verumcapsicum annuum.. A method according to claim 60 , wherein the nutrient composition further comprises or62. A method according to claim 55 , wherein the ...

Nanomedicines for early nerve repair

The present disclosure describes hydrophobically modified nanoparticles and polymeric nanostructures that can be utilized to for the treatment of neuronal injury or neuronal disease in an affected patient, along with methods of forming and using the nanoparticles and nanostructures. Furthermore, the nanoparticles and nanostructures are designed as “dual action” compositions to treat neuronal injury and neuronal disease via repair of damaged membrane and suppression of intracellular inflammation.

NOVEL USE OF PANDURATIN DERIVATIVES OR AN EXTRACT OF BOESENBERGIA PANDURATA FOR PROMOTING MUSCLE MASS GROWTH, FIGHTING FATIGUE, AND ENHANCING EXERCISE PERFORMANCE CAPABILITY

The present invention relates to the novel use of panduratin derivatives or an extract of for enhancing muscle mass growth, fighting fatigue and enhancing exercise performance. A panduratin derivative or a salt thereof or an extract of of the present invention may be used without side effect and has the effect of increasing the expression of PPAR-δ in muscles to increase muscle mass, promoting recovery from fatigue and increase mobility, thereby improving exercise performance. 1. A composition for enhancing exercise performance comprising a panduratin derivative or a salt thereof as an active ingredient.3Boesenbergia pandurata.. The composition for enhancing exercise performance of claim 1 , wherein the panduratin derivative is extracted from4Boesenbergia pandurata. A composition for enhancing exercise performance comprising an extract of as an active ingredient.5. The composition for enhancing exercise performance of any one of to claim 1 , wherein the composition is a pharmaceutical composition or a food composition.6. A composition enhancing muscle mass growth comprising a panduratin derivative or a salt thereof as an active ingredient.7Boesenbergia pandurata. A composition enhancing muscle mass growth comprising an extract of as an active ingredient.8. An anti-fatigue composition comprising a panduratin derivative or a salt thereof as an active ingredient.9Boesenbergia pandurata. An anti-fatigue composition comprising an extract of as an active ingredient.10. A method for enhancing exercise performance comprising administering an effective amount of a panduratin derivative or a salt thereof to a subject in need thereof.11. Use of a panduratin derivative or a salt thereof for preparing an agent for enhancing exercise performance.12Boesenbergia pandurata. A method for enhancing exercise performance comprising administering an effective amount of an extract of to a subject in need thereof.13Boesenbergia pandurata. Use of an extract of for preparing an agent for ...

NOVEL COMPOUND ISOLATED FROM KAEMPFERIA PANDURATA ROXB AND USE THEREOF AS ANTIVIRAL AGENT

The present invention relates to a novel compound isolated from Roxb and the use thereof as an antiviral agent. The compound isolated from Roxb shows the ability to inhibit highly pathogenic virus, and thus is a promising candidate for an antiviral agent. 1. (canceled)3Kaempferia pandurataKaempferia pandurata. A method of obtaining the compound of from Roxb , the method comprising the steps of: treating Roxb with an organic solvent to obtain an organic solvent extract; and obtaining the compound of from the organic solvent extract.4. The method of claim 3 , wherein the organic solvent is a Cto Calcohol.5. The method of claim 4 , wherein the alcohol is butanol.6. A pharmaceutical composition for preventing or treating viral disease claim 2 , comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof.7. The pharmaceutical composition of claim 6 , wherein the viral disease is avian influenza viral disease.8. The pharmaceutical composition of claim 7 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.9Kaempferia pandurata. A feed composition for preventing or treating viral disease claim 2 , comprising the compound of claim 2 , or a butanol extract of Roxb.10. The feed composition of claim 9 , wherein the viral disease is avian influenza virus.11. The feed composition of claim 10 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.12. A method for preventing or treating viral disease claim 2 , comprising a step of administering an effective amount of the compound of claim 2 , or a pharmaceutically acceptable salt thereof to a subject in need of prevention or treatment of viral disease.13. The method of claim 12 , wherein the viral disease is avian influenza viral disease.14. The method of claim 13 , wherein the avian influenza virus is H5N1-serotype avian influenza virus.15Kaempferia pandurata. Use of the compound of claim 2 , or a butanol extract of Roxb in preparation of a pharmaceutical ...

Curcuminoid composition with enhanced bioavailability and a process for its preparation

The invention relates to a curcuminoid composition with enhanced bioavailability derived from fresh turmeric rhizomes and a process for its preparation. 1. A curcuminoid composition obtained from fresh turmeric rhizomes comprising:a. 2 to 10% curcuminoids,b. 5 to 20% proteins,c. 50 to 75% carbohydrates,d. 10 to 20% dietary fiber ande. 1 to 5% of natural oils (hexane extractable),wherein each of the component is naturally derived from the fresh turmeric rhizome.2. The curcuminoid composition as claimed in claim 1 , wherein the curcuminoid component comprises of curcumin claim 1 , demethoxycurcumin claim 1 , and bisdemethoxycurcumin wherein the percentage of curcumin ranges between 50-78% claim 1 , the ratio of demethoxycurcumin ranges between 10 to 22% claim 1 , and the ratio of bisdemethoxycurcumin ranges between 5 to 24%.3Curcuma longa. The curcumnoid composition as claimed in claim 1 , wherein the composition is obtained from a fresh rhizome of L.4. The curcuminoid composition as claimed in claim 1 , wherein the percentage of curcuminoids ranges between 3 to 8% claim 1 , percentage of proteins ranges between 10 to 16% claim 1 , the percentage of carbohydrates ranges between 60 to 70% claim 1 , the percentage of dietary fiber ranges between 12 to 18% and the percentage of fixed oils is less than 3%.5. A process of making a curcuminoid composition as claimed in comprising the steps of:a. providing fresh rhizomes of turmeric,b. optionally treating the rhizomes with an enzyme,c. extracting the fresh juice from the rhizomes,d. drying the extracted juice to yield a concentrate.6Curcuma longa.. The process as claimed in claim 5 , wherein the rhizomes are selected from the species of7. The process as claimed in claim 5 , wherein the curcuminoid content in the fresh rhizome ranges from 3 to 12%.8. The process as claimed in claim 5 , wherein the extraction process in step b) can be aided with the help of ultrasonication or microwave to result maximum extractability for the ...

COMPOSITION AND METHOD FOR TREATING FAT TISSUES AND INFLAMMATORY PROCESSES

The process of the invention relates to a kit of two cosmetic, pharmaceutical, veterinary and food compositions, designed for slimming or for preventing and/or repairing inflammatory mechanisms, one of the compositions comprising at least one sirtuin activator and at least one HSP activator, and the other composition comprising at least one sirtuin inhibitor and at least one HSP inhibitor. 121-. (canceled)22. A cosmetic , pharmaceutical , food or veterinary combination comprising a first composition containing at least one sirtuin inhibitor and at least one HSP inhibitor , and a second composition containing at least one sirtuin activator and at least one HSP activator.23. The combination of claim 22 , wherein the first composition contains no sirtuin activator and no HSP activator claim 22 , and the second composition contains no sirtuin inhibitor and no HSP inhibitor.24. The combination of claim 22 , wherein the two compositions are packaged separately.25. The combination of claim 22 , wherein the combination has an increased efficacy in treatment or prevention of an inflammatory process in a patient compared to treatment with either the first or the second composition alone.26. The combination of claim 22 , wherein the combination has an increased efficacy in treatment or prevention of inflammatory processes in a patient compared to treatment with both i) a composition containing sirtuin inhibitors and no HSP inhibitor claim 22 , and ii) a composition containing sirtuin activators and no HSP activator.27. The combination of claim 22 , wherein the first composition and/or the second composition comprises at least one vascular activating agent.28. The combination of claim 27 , wherein the vascular activating agent is selected from the group consisting of AHAs (Alpha-hydroxy acids) claim 27 , and isoflavons or a plant extract containing same claim 27 , such as an extract of cassava or an extract of clover claim 27 , an extract of St. John's wort claim 27 , an ...

HERBAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES AND IMPROVING MEMORY IMPAIRMENT

The present invention relates to a composition for preventing or treating neurological diseases including an extract of fruit, red sage and as an active ingredient. The composition of the present disclosure has a superior effect of inhibiting the activity of acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine directly involved in impairment of cognitive function. In addition, the composition of the present disclosure is safe for the human body since the biologically safe extract of fruit, red sage and is used as the active ingredient. 112-. (canceled)13Euphoria longanGastrodia elata. A method for preventing or treating neurological diseases , comprising: administering to a subject a composition comprising an extract of a mixture of fruit , red sage and as an active ingredient.14. The method according to claim 13 , wherein the composition is a pharmaceutical composition or food composition.15Euphoria longanGastrodia elata. A method for improving brain or cognitive function claim 13 , comprising: administering to a subject a composition comprising an extract of a mixture of fruit claim 13 , red sage and as an active ingredient.16. The method of claim 13 , wherein the neurological disease is selected from a group consisting of degenerative nerve disease and mental disorder.17. The method of claim 16 , wherein the degenerative nerve disease is a neurological disease selected from a group consisting of dementia claim 16 , Alzheimer's disease claim 16 , Huntington's disease claim 16 , Parkinson's disease and amyotrophic lateral sclerosis.18. The method of claim 16 , wherein the mental disorder is selected from a group consisting of depression claim 16 , schizophrenia and posttraumatic stress disorder.19. The method of claim 15 , wherein the brain or cognitive function is learning ability claim 15 , memory or concentration.20. The method of claim 19 , wherein the method is for improving memory impairment.21ophiopogonCnidium officinale, Angelica ...

ADDITIVES FOR ANIMAL FOOD

The present invention relates to the combination of organic acid salts with at least one active ingredient of plant origin, preferably essential oils, partially protected with vegetable fats and/or oils, which prevent these active ingredients from being digested by stomach enzymes during the digestive process. The sodium salts of short-chain acids, preferably salts of butyric, acid are preferred. The preferred essential oils are ginger, piperine, oregano, garlic, thymol, carvacrol, cinnamaldehyde and/or any combinations thereof. The combination of organic acid salts and the essential oils protected with vegetable fats and/or oils, are used as powerful promoters or stimulants for animal growth, as organic bactericides against pathogenic bacteria present in said animals and as modulators of immune response thereof. 1. Additive for animal feed comprising the combination of a salt of an organic acid with at least one active ingredient of plant origin , this combination partially coated with vegetable oils and/or fats.2. The additive for animal feed according to wherein the organic acid are selected from the group consisting of butyric claim 1 , propionic claim 1 , formic claim 1 , lactic claim 1 , citric claim 1 , lauric claim 1 , capric claim 1 , caprylic claim 1 , caproic claim 1 , and acetic.3. The additive for animal feed according to wherein the the salt is selected from the group consisting of sodium claim 1 , calcium claim 1 , cupric and potassium.4. The additive for animal feed according to claim 1 , wherein the salt of the organic acid is preferably the sodium salt of butyric acid.5. The additive for animal feed according to claim 1 , wherein the salt of the organic acid is preferably in a proportion of 30-70% of the wet weight.6. The additive for animal feed according to wherein the active ingredients of plant origin comprise essential oils selected from the group consisting of ginger claim 1 , piperine claim 1 , oregano claim 1 , thymol claim 1 , carvacrol ...

COMPOSITIONS FOR THE SYMPTOMATIC RELIEF OF STOMACH PAIN OR GASTROOESOPHAGEAL REFLUX

Compositions useful for relieving the symptoms commonly known as stomach acidity, heartburn or, more technically, esophageal reflux (GERD), that comprise a fatty acid and a plant extract. These compositions have been tried in patients with clinical records of previous diagnosis of GERD, chronic heartburn, or esophagitis, with a high degree of success. 1. A method for re-establishment of digestive homeostasis affected by peptic acid disorders caused by damage to the gastric mucosa or digestive epithelium which comprises administering to a subject who has been diagnosed to be in need of a treatment therefor an effective amount of a composition comprising:{'sub': 1', '10, 'at least one C-Cfatty acid from the group that consists of butyric acid or isobutyric acid, alone or combined, or their alkali or alkaline-earth metal salts, or a glycerol ester thereof, and'}at least one plant extract from the alliaceae family.2. The method of claim 1 , wherein the plant extract from the alliaceae family is a garlic extract.3. The method of claim 2 , wherein the garlic extract is powdered claim 2 , non-deodorized claim 2 , dry extract.4. The method of claim 1 , wherein the alkali or a1kaline-earth metal salt of at the least one C1-C10 fatty acid is a sodium claim 1 , calcium or potassium salt thereof.5. The method of claim 4 , wherein the sodium claim 4 , calcium or potassium salt of the C1-C10 fatty acid is sodium butyrate.6. The method of claim 4 , wherein the sodium claim 4 , calcium or potassium salt of the C1-C10 fatty acid is buffered with a buffer selected front phosphate salts and carbonate salts.7. The method of claim 1 , wherein the glycerol ester of at least one C1-C10 fatty acid is a triglyceride thereof.8curcuma. The method of claim 1 , wherein a plant extract is also administered to said subject.9. The method of claim 1 , wherein the composition further comprises at least one excipient selected from the group consisting of vehiculizing agents claim 1 , thinners claim 1 ...

COMPOSITIONS COMPRISING EXTRACTS OR FRACTIONS DERIVED FROM ANNONA SQUAMOSA FOR THE PREVENTION, TREATMENT OR CONTROL OF INFLAMMATORY AND METABOLIC DISORDERS

The invention discloses synergistic composition comprising at least one derived component standardized to acetogenin compound(s) having α,β-unsaturated-γ-methyl-γ-lactone moiety in combination with at least one biologically active ingredient derived from plants, animals or microorganisms such as vitamins, amino acids, minerals, fibers, various plant and herbal extracts for the prevention, treatment, inhibition or controlling inflammation and/or metabolic disorders and other associated or related diseases. The invention further discloses the method of treating inflammation and/or metabolic disorders and other associated or related diseases. 1Annona squamosaBoswellia serrataAndrographis paniculataTerminalia chebulaCurcuma longa. Synergistic composition comprising a biologically effective extract or fraction of , said biologically effective extract comprising from 0.01 to 30% by weight of at least one compound selected from the group consisting of acetogenins having terminal α ,β-unsaturated-γ-methyl-γ-lactone moiety in combination with at least one biologically active ingredient selected from the group consisting of vitamin A , vitamin B 12 , vitamins C , Vitamin D , vitamin E , krill oil , omega-3-fatty acid , selenium , extract standardized to Boswellic acids , extract , extract , extract , magnesium , selenomethionine , selenocysteine , methylselenocycteine and mixtures thereof.3. The herbal composition according to claim 1 , wherein said acetogenins are selected from the group consisting of squamocin C (LI12103) claim 1 , isosquamocin (LI12132) claim 1 , Dieposabadelin (LI12109) claim 1 , squamostatin D (LI12106) claim 1 , squamocin L (LI12107) claim 1 , squamocin J (LI12111) claim 1 , squamocin G (LI12105) claim 1 , 10-hydroxyasimicin (LI12110); compound LI12104 claim 1 , compound LI12114 claim 1 , compound LI12115 claim 1 , compound LI12112 claim 1 , compound LI12113 claim 1 , compound LI12116 and compound LI12117.4. The compositions as claimed claim 1 , wherein ...

COMPOSITION FOR THE TREATMENT OF MIGRAINE HEADACHES AND METHODS THEREOF

Provided herein formulations of capsaicin for delivery by nasal route and methods of using the formulations for the treatment of migraines and other severe headaches. The formulations described herein contain mucoadhesives to optimize the therapeutic effect of capsaicin by intranasal delivery. 1. A composition formulated for nasal delivery comprising at least about 0.013% (w/w) capsaicin.2. The composition of claim 1 , wherein the composition comprises at least one additional therapeutic agent.3. The composition of claim 2 , wherein the therapeutic agent is ginger.4. The composition of claim 1 , wherein the composition further comprises a mucoadhesive agent.5. The composition of claim 4 , wherein the mucoadhesive agent is a microcrystalline cellulose.6. The composition of claim 1 , wherein the composition is formulated for intranasal delivery by nasal spray.7. The composition of claim 1 , wherein the concentration is from about 0.013% to 0.1% (w/w) capsaicin.8. The composition of claim 1 , wherein the concentration is from about 0.027% to 0.054% (w/w) capsaicin.9. The composition of claim 1 , wherein the concentration is about 0.0135% (w/w) capsaicin.10. The composition of claim 1 , wherein the concentration is from about 0.013% to 0.075% (w/w).11. The composition of claim 1 , wherein the concentration is about 0.027% (w/w).12. The composition of claim 1 , wherein the concentration is about 0.054% (w/w).13. A method for the treatment of a migraine claim 1 , severe or cluster headache claim 1 , comprising administering to a subject in need thereof claim 1 , a therapeutically effective amount of the composition of claim 1 , thereby treating the migraine or headache.14. The method of claim 13 , wherein the subject is a human.15. The method of claim 13 , wherein the composition is administered by nasal spray.16. The method of claim 13 , further comprising administering at least one additional therapeutic agent.17. The method of claim 16 , wherein the therapeutic agent ...

Composition to Enhance the Bioavailability of Curcumin

A composition having a curcuminoid and an essential oil of turmeric. A composition having a curcuminoid and an essential oil of turmeric, wherein the essential oil is present in an amount sufficient to cause an enhancement of bioavailability of curcumin when the composition is administered to a human as compared to bioavailability of curcumin obtained upon administration of a composition prepared without adding essential oil to the curcuminoid. A method to prepare a composition having a curcuminoid and an essential oil of turmeric. 1. A gelatin capsule comprising a composition , the composition comprising a curcuminoid mixture and an essential oil of turmeric , the composition prepared by the method comprising:suspending the curcuminoid mixture in water to form a suspension;adding the essential oil of turmeric to the suspension to form a second mixture;homogenizing the second mixture to obtain a fine slurry; anddrying the fine slurry under heat and vacuum to form a uniform blend of the composition comprising the curcuminoid and the essential oil of turmeric,wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and wherein the essential oil of turmeric comprises about 45% ar-turmerone.2. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 3:1 to about 95:5.3. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 10:1.4. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 85:15.5. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 92:8.6. The gelatin capsule of claim 1 , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric is about 95:5.7. A gelatin capsule ...

Formulation of Curcumin With Enhanced Bioavailability of Curcumin and Method of Preparation and Treatment Thereof

Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin for oral supplementation against a variety of diseases and method of doing the same is provided. 1. A method of treating rheumatoid arthritis comprising administering a composition of a curcuminoid mixture and added essential oil of turmeric , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1 , wherein the curcuminoid mixture comprises curcumin , demethoxycurcumin and bisdemethoxycurcumin , and wherein the essential oil of turmeric comprises ar-turmerone.2. A method of reducing visual analogue scale for pain comprising administering a composition of a curcuminoid mixture and added essential oil of turmeric , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1 , wherein the curcuminoid mixture comprises curcumin , demethoxycurcumin and bisdemethoxycurcumin , and wherein the essential oil of turmeric comprises ar-turmerone.3. A method of decreasing disease activity score comprising administering a composition of a curcuminoid mixture and added essential oil of turmeric , wherein the weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1 , wherein the curcuminoid mixture comprises curcumin , demethoxycurcumin and bisdemethoxycurcumin , and wherein the essential oil of turmeric comprises ar-turmerone.4. A method of improving patient response to ACR criteria comprising administering a composition of a curcuminoid mixture and added essential oil of ...

SYNERGISTIC SALIVATION AGENTS

Provides is a salivation cocktail that comprises a food acid and a tingling sensate. The combination of a food acid and a tingling sensate has been found to synergistically increase salivation. 1. A salivation cocktail composition consisting essentially of (a) at least one food acid and (b) at least one tingling sensate.2. The salivation cocktail of claim 1 , wherein the tingling sensate is selected from spilanthol claim 1 , sanshool claim 1 , hydroxyl α-sanshool claim 1 , hydroxy .beta.-sanshool claim 1 , hydroxyl γ-sanshool claim 1 , sanshool-I claim 1 , sanshool II claim 1 , sanshoamide claim 1 , japanese pepper extract claim 1 , black pepper extract claim 1 , chavicine claim 1 , piperine claim 1 , echinacea extract claim 1 , northern prickly ash extract claim 1 , Nepalese spice timer extract claim 1 , red pepper oleoresin claim 1 , 4-(1-menthoxymethyl)-2-phenyl-1 claim 1 ,3-dioxolane claim 1 , n-isobutyldeca-trans-2-trans-4-dienamide claim 1 , n-cyclopropyl claim 1 , trans-2-cis-6-nonadienamide claim 1 , n-ethyl trans-2-cis-6-nonadienamide and jambu oleoresin.3. The salivation cocktail composition of claim 2 , wherein the tingling sensate is selected from spilanthol claim 2 , sanshool and α-hydroxysanshool.4. The salivation cocktail composition of claim 3 , wherein the tingling sensate is spilanthol.5. The salivation cocktail composition of claim 4 , wherein the spilanthol is obtained from jambu oleoresin.8. The salivation cocktail composition of claim 2 , wherein the food acid is selected from acetic acid claim 2 , adipic acid claim 2 , aspartic acid claim 2 , benzoic acid claim 2 , caffeotannic acid. citric acid claim 2 , iso-citric acid claim 2 , citramalic acid claim 2 , formic acid claim 2 , fumaric acid claim 2 , galacturonic acid claim 2 , glucuronic acid claim 2 , glyceric acid claim 2 , glycolic acid claim 2 , ketoglutaric acid claim 2 , a-ketoglutaric acid claim 2 , lactic acid claim 2 , lactoisocitric acid claim 2 , malic acid claim 2 , oxalacetic ...

COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING MALNUTRITION

Provided herein are compositions and methods for treating, preventing, and reversing malnutrition. In particular, provided herein are compositions and methods for facilitating cognitive repair and preventing obesity (e.g. in children). 193.-. (canceled)94. A composition for the treatment and prevention of malnutrition , comprising:a) at least 20 mg of a plurality of flavonoids, wherein at least a portion of the flavonoids cross the blood-brain barrier, wherein at least one of said flavonoids is catechin or epicatechin; b) at least 0.1 g of omega-3 fatty acids, wherein said omega-3 fatty acids comprise EPA and DHA;c) at least 1 mg caffeine; d) a plurality of micronutrients selected from the group consisting of iron, phosphorous, zinc, thiamine, riboflavin, niacin, vitamin B6, folate, vitamin, B12, pantothenic acid, biotin, choline, chromium, copper, manganese, seleniusm, molybdenum, iodine, vitamin A, calcium, potassium, magnesium, vitamin E, vitamin C, a carotenoid, vitamin D, and vitamin K; and e) a sufficient amount of energy comprising 11-35% of calories from protein, 10-50% of calories from carbohydrates, and 30-60% of calories from fat.95. The composition of claim 94 , wherein said composition comprises 20-2000 mg of flavonoids.96. The composition of claim 94 , wherein said composition comprises at least 200 mg of flavonoids.97. The composition of claim 94 , wherein said composition comprises 200-500 mg of catechin and/or epicatechin.98. The composition of claim 94 , wherein said catechin and/or epicatechin are in or obtained from cocoa and/or green tea.99. The composition claim 94 , wherein said flavonoids are derived from a plant or plant component selected from the group consisting of cocoa claim 94 , green tea claim 94 , black tea claim 94 , tea extracts claim 94 , quercetin claim 94 , green vegetables claim 94 , spinach claim 94 , moringa claim 94 , matcha claim 94 , kaempferol claim 94 , kale claim 94 , tomato claim 94 , acai berry claim 94 , blueberry ...

TREATMENT OF PETS WITH SIRTUIN ACTIVATORS

The present invention provides for systems, compositions, methods and kits for regulating energy metabolism in pets. The systems, compositions, and kits can comprise, and methods can make use of, pet foods, pet treats, pet supplements, and pet drinks. In one aspect, the invention provides for pet food, treat, supplement, and drink compositions that comprise a combination of (a) leucine, and (b) a sirtuin activator, or any precursors or metabolites of (a) or (b). These combinations may be effective for reducing weight or adipose volume in the pet. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising leucine, a leucine metabolite, and/or a sirtuin activator. The invention also provides for kits comprising compositions of leucine, a leucine metabolite, and/or a sirtuin activator packaged in an oral dose form with usage instructions. 1. A pet food composition comprising:a. about 0.05 to 5 wt % of leucine and/or about 0.005 to 1 wt % of one or more leucine metabolites; andb. about 0.0005 to 0.05 wt % of a sirtuin activator.2. A pet food , treat or supplement composition comprising:a. at least about 50 mg of leucine and/or at least about 5 mg of one or more leucine metabolites; andb. at least about 1 mg of a sirtuin activator.3. A pet food composition comprising:a. about 0.05 to 5 wt % of leucine and/or about 0.005 to 1 wt % of one or more leucine metabolites;b. about 0.0005 to 0.05 wt % of a sirtuin activator; andc. an additional component selected from the group consisting of omega-3 fatty acid, eicosapentanoic acid, choline, manganese, methionine, cysteine, L-carnitine, lysine, alpha lipoic acid, dimethylaminoethanol, pyruvic acid, actyl L-carnitine, L-carnitine, conjugated linoleic acid, diacylglyceride, chondroitin, glucosamine, ginger (or extract thereof), chicory pulp, and myrtle.4. A pet food , treat or supplement composition comprising:a. at least about 50 mg of leucine ...

A COMPOSITION FOR IMPROVING JOINT HEALTH, OR FOR PREVENTING AND TREATING RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS

The present invention relates to a composition for helping with joint health or preventing, alleviating or treating rheumatoid arthritis and osteoarthritis, which is based on the results of tests conducted using an inflammatory cell model, an osteoarthritis animal model and an acute arthritis animal model. 1. A composition for helping with joint health or preventing , alleviating or treating rheumatoid arthritis and osteoarthritis , which contains , as an active ingredient:an extract mixture obtained by extracting each of Kalopanacis Cortex, Chaenomelis Fructus, Angelicae Gigantis, Zingiberis Rhizoma Crudus, Raphani Semen and Saururi Herba to prepare extracts, and mixing the extracts with one another at a mixing ratio of 150-250 parts by weight of the Kalopanacis Cortex extract: 650-750 parts by weight of the Chaenomelis Fructus extract: 650-750 parts by weight of the Angelicae Gigantis extract: 50-150 parts by weight of the Zingiberis Rhizoma Crudus extract: 50-150 parts by weight of the Raphani Semen extract: 150-250 parts by weight of the Saururi Herba extract; ora dry extract mixture obtained by drying each of the extracts and mixing the dried extracts with one another at the above mixing ratio; or a mixed extract obtained by mixing Kalopanacis Cortex, Chaenomelis Fructus, Angelicae Gigantis, Zingiberis Rhizoma Crudus, Raphani Semen and Saururi Herba with one another at the above mixing ratio to prepare a mixture, and extracting the mixture.2. The composition of claim 1 , which has effects on inhibition of inflammatory cytokines and matrix metalloproteinases (MMPs) claim 1 , relief of inflammation and pain claim 1 , enhancement of activity of cartilage formation factors claim 1 , and normalization of a joint structure.3. The composition of claim 1 , wherein a number of times the extraction is performed when each of the extracts or mixed extract is prepared is two or more.45-. (canceled)6. A pharmaceutical composition for alleviating or treating rheumatoid ...

COMPOSITION FOR PREVENTING CANCER AND TREATING CANCER AND INTENSIFYING THE EFFECTS OF OTHER ANTICANCER DRUGS

This invention relates to a composition derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to its use for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs. More specifically, the composition of the present invention is derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The composition of the invention is obtained through specific techniques and has revealed good cytotoxicities on Malignant Melanoma Cells, Prostate Cancer Cells and Colon Cancer Cells, Lung Cancer Cells, Stomach Cancer Cells, Breast Cancer Cells and Liver Cancer Cells. The composition of the invention has also revealed obvious intensifying the effects of other anticancer drugs. Cancer presents special problems to the medical community which the present invention address, 1. A method for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs , said method is a plant aqueous extract comprises PRUNELLAE SPICA , SCUTELLARIAE BARBATAE HERBA , ANTRODIA CAMPHORATA , CURCUMAE RHIZOMA , PAEONIAE SUFFRUTICOSAE CORTEX , PATRINIAE HERBA , IXERIS HERBA and PHELLINUS LINTEUS extracts.2. The method according to wherein the weight ratio of PRUNELLAE SPICA:SCUTELLARIAE BARBATAE HERBA:ANTRODIA CAMPHORATA:CURCUMAE RHIZOMA:PAEONIAE SUFFRUTICOSAE CORTEX:PATRINIAE HERBA:IXERIS HERBA:PHELLINUS LINTEUS is about(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5):(0.5˜1.5).3. The method according to wherein said therapeutically effective amount is 0.4 to 120 grams per day.4. The method according to wherein the composition is administered to the subject by orally or nasally or cutaneously or parentally or anally or virginally or via eye or via ear or by spray inhalation or by implanted reservoir or operation or acupuncture.5. The method according to wherein said plant aqueous extract is in a form selected from the group consisting of ...

HOMEOPATHIC METHOD FOR TREATING COLIC, GAS AND UPSET STOMACH IN INFANTS

The present invention generally relates to homeopathic compositions, and, more particularly, (i) homeopathic compositions comprising a homeopathically potentised form of (Passionflower), and a homeopathically potentised form of (Nutmeg); or (ii) a homeopathically potentised ; and a homeopathically potentised ; or (iii) a homeopathically potentised ; and a homeopathically potentised ; and methods of treatment using these homeopathic compositions. 142-. (canceled)43Carbo Vegetabilis. A homeopathic composition comprising homeopathically potentised formulated in a liquid suspension.44Carbo Vegetabilis. The homeopathic composition of claim 43 , wherein the homeopathically potentised form of the is at a potency of 1× or 2×.45Carbo Vegetabilis. The homeopathic composition of claim 43 , wherein the is triturated with a sugar alcohol selected from the group consisting of Xylitol claim 43 , Mannitol and Sorbitol or a combination thereof.46Carbo Vegetabilis. The homeopathic composition of claim 43 , wherein the is produced from activated carbon having an iodine number of at least 900 mg/g.47Carbo Vegetabilis. The homeopathic composition of claim 43 , wherein the comprises activated carbon particles having a mean particle size of about 15 microns to about 60 microns with at least 90% of mass contained in particles (% Подробнее

Compositions for Relieving the Symptoms of Gluten Sensitivity and Methods of Use Thereof

The disclosure relates to a composition that may be used to prevent the symptoms of non-celiac gluten sensitivity and may include ingredients that degrade or inactivate gluten and other components that may cause these symptoms. 1. A composition for reducing gluten sensitivity , comprising at least three proteases;at least one carbohydrase;at least one probiotic; andwherein said composition relieves symptoms of gluten sensitivity.2. The composition of further comprising ginger and turmeric.3. The composition of wherein said composition relieves the symptoms of non-celiac gluten sensitivity.4Aspergillus oryzaeAspergillus melleus. The composition of wherein said at least three proteases are selected from the group consisting of Protease 3.0 claim 1 , Protease 4.5 claim 1 , Protease 6.0 claim 1 , Papain claim 1 , Bromelain claim 1 , Protease claim 1 , Protease claim 1 , Proteases I-V claim 1 , and DPP IV and combinations thereof.5. The composition of wherein said at least one carbohydrase is selected from the group consisting of lactase claim 1 , α-galactosidase claim 1 , β-glucanase claim 1 , xylanase claim 1 , glucoamylase claim 1 , amylase claim 1 , hemicellulase claim 1 , invertase and pectinase and combinations thereof.6Lactococcus lactisLactococcus cremoris.. The composition of wherein said at least one probiotic is selected from the group consisting of and7. The composition of wherein said composition prevents the symptoms of non-celiac gluten sensitivity where said symptoms are selected from the group consisting of abdominal pain claim 1 , cramping claim 1 , bloating/distention claim 1 , diarrhea claim 1 , constipation and fatigue and combinations thereof.8. The composition of wherein said symptoms of non-celiac gluten sensitivity are selected from the group consisting of abdominal pain claim 7 , bloating claim 7 , changes in bowel habits and fatigue and combinations thereof.9. The composition of wherein said composition reduces the concentration of gluten to ...

FERMENTED MINERAL RAW-EDIBLE PILL WITH CONSTIPATION REDUCTION AND FATIGUE RECOVERY AND METHOD FOR PRODUCING THE SAME

The invention relates to a method for producing a fermented mineral pill with constipation reduction and fatigue recovery, the method comprising: cultivating using a rice straw; fermenting at least one of a rice-husk powder, a rice-bran powder and a lentil bean power using the to acquire a fermented mixture; and shaping and drying the fermented mixture into solid pills. 1. A method for producing a fermented mineral raw-edible pill with constipation reduction and fatigue recovery , the method comprising:{'b': '1', '(S) mixing a nuruk, a finely-cut rice straw, and a barley malt with a water, wherein the nuruk 1 to 10 percentage by weight to obtain a first mixture, the barley malt 10 to 20 percentage by weight and the finely-cut rice straw 10 to 30 percentage by weight are based on the water 100 percentage by weight, and aging the first mixture at 26 to 35° C. for 2 to 4 day to acquire a rice straw fermented liquid;'}{'b': 2', '1, '(S) mixing a rice straw powder and a rice-husk powder with each other at a mixing ratio 1:2 to 2:1 by weight to acquire a second mixture, and adding and kneading the second mixture into the rice straw fermented liquid produced from the step (S) to acquire a third mixture, wherein the rice straw fermented liquid 20 to 60 percentage by weight is based on the second mixture 100 percentage by weight, and fermenting the third mixture at 35 to 45° C. for 65 to 75 hours, and drying the third mixture for 10 to 20 days in a shady place;'}{'b': 3', '1, '(S) mixing a rice straw powder and a rice-bran powder with each other at a mixing ratio 1:2 to 2:1 by weight to acquire a fourth mixture, and adding and kneading the fourth mixture into a further rice straw fermented liquid produced from the step (S) to acquire a fifth mixture, wherein the further rice straw fermented liquid 20 to 60 percentage by weight is based on the fourth mixture 100 percentage by weight, and fermenting the fifth mixture at 35 to 45° C. for 65 to 75 hours, and drying the fifth ...

PLANT TISSUE-DERIVED NANOPARTICLES AND FOOD POWDERS

Provided herein are nanoparticles including self-assembled cellular components derived from a homogenized plant tissue. Also provided are food powders and other related compositions. Methods for preparing such nanoparticles and food powders, as well as uses thereof in the treatment or prevention of diseases or disorders in a subject and/or as delivery vehicles are also described. 1. A nanoparticle comprising self-assembled cellular components derived from a homogenized plant tissue , the cellular components comprising one or more structural carbohydrates or cleavage products thereof , wherein lipids are not a structural component of the nanoparticle.2. The nanoparticle of claim 1 , wherein the nanoparticle is substantially lipid-free.3. The nanoparticle of or claim 1 , wherein the nanoparticle comprises pectin claim 1 , hemicellulose claim 1 , peptide and/or protein claim 1 , an organic acid claim 1 , at least one polyphenol claim 1 , cleavage products thereof claim 1 , or any combination thereof.4. The nanoparticle of any one of - claim 1 , wherein the nanoparticle comprises:a pectin-based inner core;an intermediate layer surrounding the inner core, the intermediate layer comprising macromolecules of pectin and hemicellulose and/or cleavage products thereof, polyphenol, and organic acid; anda fibrillated outer layer comprising macromolecular carbohydrate and protein, optionally formed from catabolism during ripening and/or during homogenization of the plant tissue.5. The nanoparticle of or claim 1 , wherein the organic acid comprises malic acid claim 1 , ascorbic acid claim 1 , or both.6. The nanoparticle of any one of - claim 1 , wherein the polyphenol comprises an anthocyanin.7. The nanoparticle of any one of - claim 1 , wherein the cellular components comprise those liberated from the plant tissue during ripening or during homogenization of ripened fruit claim 1 , which are capable of self-assembling into the nanoparticle.8. The nanoparticle of any one of - ...

METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS

Embodiments of the present invention are directed to formulations and methods of treating folic acid deficiency and morning sickness. The dosage form has an effective amount, of a folic add with an effective amount of a gingerol composition to suppress nausea and/or gastric distress and to promote hematopoiesis. 1. A dosage form for the treatment of folic acid deficiency and morning sickness comprising an effective amount of an folic acid selected from a group comprising natural and synthetic forms of Vitamin B-9 , one of the B-complex vitamins and mixtures thereof , with an effective amount of a gingerol composition to suppress nausea and/or gastric distress , said gingerol composition selected from a group of gingerol compounds comprising 6-gingerol , 8-gingerol , 10-gingerol , 12-gingerol , 6-shogaol , 8-shogaol and 10-shogaol as single compositions and mixtures thereof.2. The dosage form of further comprising an oil base wherein the folic acid is dispersed as a solid suspension in said oil base and said gingerol composition dissolved in said oil base.3. The dosage form of wherein said oil base is held in a gel cap.4. The dosage form of wherein said gingerol composition is an extract from a ginger compound containing natural source.5. The dosage form of wherein said gingerol composition is used to wet a powder of said folic acid to form a gingerol wetted folic acid powder.6. The dosage form of wherein said gingerol wetted folic acid powder is pressed into a tablet.7. The dosage form of wherein said gingerol wetted folic acid powder is loaded into a capsule.8. The dosage form of wherein said folic acid and gingerol are dissolved or suspended in a solution.9. The dosage form of wherein said folic acid is present in 400 to 800 mcg of folic acid.10. The dosage form of wherein said gingerol composition is present in an amount effective to promote hematopoiesis.11. A method of treating morning sickness comprising the administering of a dosage form comprising an ...

Composition to Mitigate Spikes in Blood Sugar

Compositions comprising therapeutically effective amounts of quercetin, myricetin and chlorogenic acid are improved by the addition of one or multiple additional components, for mitigating blood sugar spikes in general and for treating diabetes specifically. Certain other additives produce additional benefits. 1. A composition comprising therapeutically effective amounts of quercetin , myricetin and chlorogenic acid in combination with curcumin.2. The composition according to claim 1 , wherein the curcumin is in an amount no greater than 12 g.3. The composition according to claim 2 , wherein the amount of curcumin is greater than 50 mg.4. The composition according to claim 1 , wherein the curcumin is in the form of an extract of turmeric root.5. The composition according to claim 1 , further comprising an agent that increases bioavailability of the curcumin in humans by at least 50%.6. The composition according to claim 5 , wherein the agent includes piperine.7. The composition according to claim 6 , wherein the piperine is in an amount greater than 20 mg.8. The composition according to claim 1 , wherein the agent is in the form of black pepper.9. The composition according to claim 1 , in combination with dried tea leaves.10. The composition according to claim 9 , wherein the composition and the dried tea leaves are combined in a flow through tea bag.11. The composition according to claim 9 , wherein content of the tea bag is characterized by no more than a trace amount of an agent that increases bioavailability of the curcumin in humans.12. A composition comprising therapeutically effective amounts of quercetin claim 9 , myricetin and chlorogenic acid in combination with capsicum.13. The composition according to claim 12 , wherein the capsicum is in an amount no greater than 8 g.14. The composition according to claim 13 , wherein the amount of capsicum is greater than 2 g.15. The composition according to claim 12 , wherein the capsicum is in the form of an extract ...

ADRENOMEDULLIN PRODUCTION ENHANCER

It is an object of the invention to discover a substance that effectively increases the production of adrenomedullin, as well as to provide an adrenomedullin production-enhancing agent utilizing this substance. The adrenomedullin production-enhancing agent is characterized by inclusion of a ginsenoside, a sanshool, and/or a shogaol as active ingredients. 2. The method according to claim 1 , wherein the compound represented by formula (1) is at least one ginsenoside selected from the group consisting of ginsenoside Rb claim 1 , ginsenoside Rb claim 1 , ginsenoside Rc claim 1 , ginsenoside Rd claim 1 , ginseonside Re claim 1 , ginsenoside Rg claim 1 , ginsenoside Rg claim 1 , and ginsenoside Rh.3. The method agent according to claim 1 , wherein the compound represented by formula (2) is at least one sanshool selected from the group consisting of α-sanshool claim 1 , β-sanshool claim 1 , γ-sanshool claim 1 , hydroxy-α-sanshool claim 1 , hydroxy-β-sanshool claim 1 , and hydroxy-γ-sanshool.4. The method according to claim 1 , wherein the compound represented by formula (3) is at least one compound selected from the group consisting of 6-shogaol claim 1 , 8-shogaol claim 1 , and 10-shogaol.6. The method according to claim 5 , wherein the crude drug comprising the compound represented by formula (1) is ginseng.7. The method according to claim 5 , wherein the crude drug comprising the compound represented by formula (2) is Japanese pepper.8. The method according to claim 5 , wherein the crude drug containing the compound represented by formula (3) is dried ginger rhizome.10. The method according to claim 9 , wherein the Kampo medicine prescription is Daikenchutou.1120-. (canceled) The present invention relates to an adrenomedullin production-enhancing agent, and more particularly to an adrenomedullin production-enhancing agent that is effective in preventing and treating diseases such as Crohn's disease by promoting the production of adrenomedullin, an intestinal peptide ...

MODIFIED CYCLODEXTRIN COATED MAGNETITE NANOPARTICLES FOR TARGETED DELIVERY OF HYDROPHOBIC DRUGS

The invention discloses a composition comprising surface modified iron oxide nanoparticles with citric acid modified cyclodextrin with a hydrodynamic diameter of less than 10 nm and a hydrophobic molecule. 1. Beta-cyclodextrin-citrate coated magnetic nanoparticles of size 3 to 10 nm.2. A process for the preparation of Beta-cyclodextrin-citrate coated magnetic nanoparticles comprising the steps of:i. dissolving β-cyclodextrin and citric acid in a ratio ranging between 3:1 to 5:2 in water followed by stirring the mixture at a temperature in a range of 70-80° C. for period in the range of 3-4 hrs to obtain a transparent solution;ii. treating the transparent solution as obtained in step (i) with alcohol, followed by washing and drying at a temperature in the range of 60-70° C. for a period in the range of 24-26 hrs to obtain cyclodextrin-citrate complex;iii. dissolving cyclodextrin-citrate complex as obtained in step (ii) in water to obtain a cyclodextrin-citrate solution;iv. mixing ferric chloride hexahydrate and ferrous chloride tetrahydrate molar ratio ranging from 2:1 to 5:3 in water and ammonium hydroxide solution followed by stirring and washing to obtain magnetic nanoparticle;v. redispersing the magnetic nanoparticles as obtained in step (iv) followed by adding the Cyclodextrin-citrate solution as obtained in step (iii) with stirring for period in the range of 4-5 hours at temperature in the range of 80-90° C. to obtain a stable dispersion of beta-cyclodextrin coated magnetite nanoparticles;vi. dialyzing the beta-cyclodextrin coated magnetite nanoparticles dispersion obtained in step (v) against water for a period in range of 3-4 days and at a temperature in the range of 60-70° C. to obtain coated solid nanoparticles;vii. dispersing the coated nanoparticles obtained in step (vi) in water at the physiological pH to obtain Beta-cyclodextrin-citrate coated magnetite nanoparticles;3. The Beta-cyclodextrin-citrate coated magnetic nanoparticles as claimed in claim 1 , ...

USE OF TWO BOTANICALS WITH COMPLEMENTARY ACTIVITIES FOR IMPROVEMENT OF SKIN

A skin augmentation composition comprises a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. Methods for enhancing the repair of damaged skin and the prevention of developing wounds in a subject having damaged skin comprises administering to a portion of damaged skin, a composition comprising a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. 19.-. (canceled)10. A method for augmenting skin , the method comprising administering to the skin a composition comprising 1% to 20% (w/v) curcumin , 0.1% to 10% (w/v) 6-gingerol , and a carrier suitable for topical application wherein the carrier comprises an emollient , wherein the composition is applied to augment chronologically aged skin , diabetic skin , or photoaged skin.1117-. (canceled)18. The method of claim 10 , wherein the composition is applied to augment chronologically aged skin.19. The method of claim 10 , wherein the composition is applied to augment diabetic skin.20. The method of claim 10 , wherein the composition is applied to augment photoaged skin.2122-. (canceled)23. The method according to claim 10 , wherein the composition comprises ginger extract.24. The method according to claim 10 , wherein the composition comprises turmeric extract.25. The method according to claim 10 , wherein the composition comprises ginger extract and turmeric extract.26. The method according to claim 10 , wherein the composition comprises about 10% curcumin (w/v) and about 3% 6-gingerol (w/v).27. The method according to claim 10 , wherein the composition further comprises a member selected from the group consisting of: demethoxycurcumin claim 10 , bisdemethoxycurcumin claim 10 , (1E claim 10 ,4Z claim 10 ,6E)-5-hydroxy-1 claim 10 ,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1 claim 10 ,4 claim 10 ,6-trien-3-one claim 10 ,1 claim 10 ,7-bis(4-hydroxy-3 ...

COMPOSITION FOR RELIEVING STRESS AND ENHANCING IMMUNITY AND PREPARATION METHOD THEREOF

The invention belongs to the technical field of health food and particularly relates to a composition for relieving stress and enhancing immunity and a preparation method thereof. The composition for relieving stress and enhancing immunity is calculated in parts by weight, 100-300 parts of a radix curcuma extract, 100-250 parts of a sea cucumber extract, 100-250 parts of a chlorella extract, 50-150 parts of a cranberry extract, 100-300 parts of a ginseng extract, 80-150 parts of a coconut oil extract and 100-200 parts of a palm oil extract. The composition can significantly enhance the body's immunity, relieve mental stress and improve the level of human health. In addition, the composition of the present invention is suitable for long-term use and has a small adverse reaction. 1. A composition for relieving stress and enhancing immunity , characterized in , the composition for relieving stress and enhancing immunity is calculated in parts by weight , 100-300 parts of a turmeric extract , 100-250 parts of a sea cucumber extract , 100-250 parts of a chlorella extract , 50-150 parts of a cranberry extract , 100-300 parts of a ginseng extract , 80-150 parts of a coconut oil extract , and 100-200 parts of a palm oil extract.2. The composition for relieving stress and enhancing immunity according to claim 1 , characterized in claim 1 , the composition for relieving stress and enhancing immunity is calculated in parts by weight claim 1 , further comprising 50-100 parts of lecithin and 50-80 parts of 5-hydroxytryptophan.3. The composition for relieving stress and enhancing immunity according to claim 1 , characterized in claim 1 , the composition for relieving stress and enhancing immunity is calculated in parts by weight claim 1 , 150-250 parts of a turmeric extract claim 1 , 100-200 parts of a sea cucumber extract claim 1 , 150-200 parts of a chlorella extract claim 1 , 80-100 parts of a cranberry extract claim 1 , 150-250 parts of a ginseng extract claim 1 , 100-150 ...

EDICINE COMPOSITION FOR TREATMENT OF HUMAN PAPILLOMAVIRUS INFECTION AND PREPARATION METHOD THEREOF

A pharmaceutical composition, including: 30-60 parts by weight of Root; 10-20 parts by weight of Cinnamon Twig; 10-20 parts by weight of Chinese Knotweed; and 10-20 parts by weight of 1. A pharmaceutical composition , comprising:{'i': 'Smilax Glabra', '30-60 parts by weight of Root;'}10-20 parts by weight of Cinnamon Twig;10-20 parts by weight of Chinese Knotweed; and{'i': 'Commelina Communis.', '10-20 parts by weight of'}2. The pharmaceutical composition of claim 1 , comprising:{'i': 'Smilax Glabra', '30-55 parts by weight of Root;'}12-18 parts by weight of Cinnamon Twig;10-18 parts by weight of Chinese Knotweed; and{'i': 'Commelina Communis.', '12-18 parts by weight of'}3. A pharmaceutical preparation claim 1 , comprising the pharmaceutical composition of .4. The pharmaceutical preparation of claim 3 , having a dosage form of creams claim 3 , lotions claim 3 , gels claim 3 , or suppositories.5. A method of preparing the pharmaceutical preparation of claim 3 , the method comprising:{'i': Smilax Glabra', 'Commelina Communis, '1) mixing 30-60 parts by weight of Root, 10-20 parts by weight of Cinnamon Twig, 10-20 parts by weight of Chinese Knotweed, and 10-20 parts by weight of , thus yielding a mixture;'}2) dissolving the mixture in a solvent, decocting the mixture dissolved in the solvent, thus yielding a first filtrate and a first residue;3) collecting the first filtrate, dissolving the first residue in the solvent, and decocting the first residue dissolved in the solvent, thus yielding a second filtrate and a second residue;4) repeating 3), mixing collected filtrates, and condensing the filtrates to yield an extract having a relative density of 1.10-1.40 at 60° C.6. The method of claim 5 , wherein the solvent is an ethanol solution; the ethanol solution has a concentration of 50-80% (v/v) claim 5 , and a volume weight ratio of the ethanol solution to the mixture is 5-15.7. The method of claim 5 , wherein the solvent is water.8. The method of claim 5 , wherein in 2 ...

MEDICAMENT COMPRISING GINGER ROOT CO2 EXTRACT

The present invention belongs to the fields of pharmaceuticals and cosmetics, and concerns on the one hand a medicament for the inhibition of and refers also on the cosmetic, non-therapeutic use for the treatment of hyperpigmentation, particularly induced by sun light radiation, preferably induced by visible light radiation. 1. A medicament containing at least a ginger root CO2 extract for use in the treatment , prevention and/or amelioration of hyperpigmentation.2. The medicament of claim 1 , wherein the hyperpigmentation is induced by the radiation of sunlight.3. The medicament of claim 1 , wherein the hyperpigmentation is induced by the radiation of visible light.4. The medicament of claim 1 , wherein the ginger root CO2 extract contains(a) 15 to 30% b.w. [6]-gingerol;(b) 3 to 10% b.w. [8]-gingerol;(c) 3 to 10% b.w. [10]-gingerol;(d) 0.5 to 4% b.w. [6]-shogaol;(e) 0.03 to 1.3% b.w. [8]-shogaol;(f) 0.03 to 1% b.w. [10]-shogaol; and(g) 0.01 to 1% b.w. zingerone,on condition that the amount of gingerols sums up to 24 to 50% b.w. and the amount of shogaols sums up to 0.5 t 6% b.w.5. The medicament of claim 1 , wherein the medicament further comprises at least one UV filter selected from the group consisting of UV-A filters claim 1 , UV-B filters claim 1 , light protection pigments and mixtures thereof.6. The medicament of claim 1 , wherein the medicament further comprises at least one skin lightening agent.7. The medicament of claim 1 , wherein the ginger root CO2 extract is present in an active amount to reduce claim 1 , retard claim 1 , suppress and/or protect against sunlight claim 1 , preferably visible light induced hyperpigmentation.8. A medicament comprising{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'claim-text': 'at least one compound selected from (b1), (b2) and (b3):', '(a) from 0.001 wt. % to 1 wt. % of a ginger root CO2 extract as defined in , and'}(b1) from 0.05 wt. % to 60 wt. % of UV filters,(b2) from 0.005 wt. % to 20 wt. % of skin lightening ...

Fucoidan hair growth agent

To develop a novel administration method of a fucoidan-containing hair-growing agent and to provide a means for exerting excellent effects of a fucoidan. A hair-growing agent of the present invention is characterized in that it is composed of a combination of a fucoidan-containing microneedle and a fucoidan-containing liniment. A base of the fucoidan-containing microneedle is preferably a biosoluble polymer. A hair-growing method of the present invention is characterized in that the fucoidan-containing microneedle and the fucoidan-containing liniment are concomitantly used.

Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases

A composition including a mixture of at least two different honeys is used to treat a variety of medical conditions. The composition can be administered topically, orally, by inhalation or parenterally. The composition is useful in treating wounds, infections, diabetes, skin conditions, renal conditions, dehydration, malnutrition, hypertension and various other conditions. It has been found that the mixture of at least two different types of honey, either alone or in combination with other bee products is more effective than the administration of single honey.

COMPOSITIONS FOR MANAGEMENT OF WOUNDS, SKIN DISEASES, DEHYDRATION, CHRONIC DISEASES, AND RESPIRATORY DISEASES

A composition including a mixture of honey, curcumin, propolis or CAPE or any two of them is used to treat a variety of medical conditions. The composition can be administered topically, orally, by inhalation or parenterally. The composition is useful in treating wounds, infections, diabetes, skin conditions, renal conditions, dehydration, malnutrition, hypertension and various other conditions. The mixture of honey, curcumin, and propolis or CAPE, either alone or in combination with other natural products is more effective than the administration of single ingredient. 1. A composition for treatment of a medical condition , comprising a mixture of at least two of the following components: honey , curcumin and propolis (or CAPE).2Arabica, nigella sativa. The composition according to claim 1 , further comprising at least one of the following additional ingredients: bee venom or melittin claim 1 , royal jelly or mixed royal jelly claim 1 , bee pollen or mixed bee pollen claim 1 , acacia or thymoquinone claim 1 , clove or clove oil claim 1 , olive oil claim 1 , garlic claim 1 , flaxseed or flaxseed oil claim 1 , fish oil claim 1 , green tea claim 1 , fenugreek seeds claim 1 , walnuts claim 1 , date seeds claim 1 , whey protein claim 1 , peanuts claim 1 , other nuts claim 1 , and ginger.3. The composition according to claim 1 , wherein the the mixture contains any two of the following components: honey in an amount of 10-99 wt % claim 1 , curcumin in an amount of 5-20 wt % and propolis in amount of 1-30 wt % or CAPE in amount of 0.1-1000 micromole/100 g.4. The composition according to claim 1 , wherein the composition is formulated for topical application to the skin.5. The composition according to claim 1 , wherein the composition is configured for parenteral administration.6. The composition according to claim 1 , wherein the composition is configured for inhalation.7. The composition according to claim 1 , wherein the composition is configured for oral administration. ...

METHOD FOR TREATING AN ALLERGIC DISEASE

The invention relates to a use of a compound for manufacturing a medicament for treating an allergic disease, wherein the compound is selected from the group consisting of ovatodiolide, 1′-acetoxychavicol acetate, zerumbone and combination thereof. Also provided is a method and a composition for treating an allergic disease. 1. A method for treating an allergic disease which comprises administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of ovatodiolide , 1′-acetoxychavicol acetate , zerumbone and combination thereof2. The method of claim 1 , wherein the compound is administered in a pharmaceutical composition.3Anisomeles indica, Alpinia galangal, Zingiber zerumbet. The method of claim 1 , wherein the compound is administered in a composition comprising an extract from an herb selected from the group consisting of and combination thereof.4. The method of claim 1 , wherein the allergic disease is selected from the group consisting of hay fever claim 1 , food allergies claim 1 , atopic dermatitis claim 1 , asthma claim 1 , psoriasis claim 1 , anaphylaxis psoriasis claim 1 , atopic dermatitis claim 1 , contact dermatitis or eczema claim 1 , autoimmune disease claim 1 , osteoarthritis claim 1 , allergy rhinitis claim 1 , seborrheic dermatitis claim 1 , psoriasis arthritis and poison ivy.5. The method of claim 4 , wherein the allergic disease is allergic dermatitis.6. The method of claim 5 , wherein the allergic dermatitis is atopic dermatitis.7. The method of claim 5 , wherein the allergic dermatitis is psoriasis.8. The method of claim 4 , wherein the allergic disease is autoimmune disease.9. The method of claim 8 , wherein the autoimmune disease is selected from the group consisting of autoimmune hepatitis claim 8 , autoimmune pancreatitis claim 8 , Sjogren' syndrome claim 8 , ulcerative colitis claim 8 , Crohn's disease claim 8 , reflex sympathetic dystrophy claim 8 , post myocardial infarction ...

CURCUMIN-CONTAINING MEDICINAL PREPARATION

An object of the present invention is to provide a curcumin-containing solid composition to be used as a composition for treating or preventing diseases and symptoms that benefit from curcumin absorption into cells. 1. A method for treating or preventing a disease or symptom that benefits from curcumin absorption into cells , the method comprising administering a solid composition comprising:(1) curcumin;(2) hydrophilic polymer; and(3) at least one nonionic surfactant selected from the group consisting of polyglycerol fatty acid esters, sucrose fatty acid esters, and lecithins,to a subject in need thereof.2. The method according to claim 1 , wherein the disease or symptom is at least one member selected from the group consisting of:(1) diseases or symptoms that benefit from modulation of one or more transcription factors selected from the group consisting of NF-κB, AP-1, STAT, Wnt/β-catenin, Notch-1, EGR-1, CREB-BP, WT-1, HIF, ERE, Nrf-2, PPAR-α, and PPAR-γ;(2) diseases or symptoms that benefit from modulation of one or more cytokines selected from the group consisting of TNF-α, IL-2, IL-5, IL-6, IL-8, IL-12, IL-18, MCP-1, MIP-1α, and MaIP;(3) diseases or symptoms that benefit from modulation of one or more receptors selected from the group consisting of IR, ER-α, H2R, HER-2, LDLR, ITR, FasR, EPCR, AR, EGFR, IL-8R, CXCR4, AHR, and DR-5;(4) diseases or symptoms that benefit from modulation of one or more enzymes selected from the group consisting of Desaturase, GCL, AATF-1, ATFase, Telomerase, MMP, ATPase, GICL, COX-2, iNOS, NQO-1, 5-LOX, TMMP-3, DNA pol, Src-2, FPT, PhP D, GST, ODC, and ACOX-1;(5) diseases or symptoms that benefit from modulation of one or more growth factors selected from the group consisting of HGF, CTGF, FGF, NGF, PDGF, TGF-β1, EGF, VEGF, and TF;{'sup': '2+', '(6) diseases or symptoms that benefit from modulation of one or more kinases selected from the group consisting of FAK, AAPK, P60c-tk, EGFR-K, CaPK, PTK, MAPK, IL-1R AK, PKB, PKA, PAK, JAK, ...

CAPSULE-CONTAINING POUCHED PRODUCT FOR ORAL USE

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical. 1. A pouched product adapted for oral use , comprising:a water-permeable fabric pouch formed so as to define a cavity therein;a composition contained within the cavity of the water-permeable fabric pouch, the composition comprising one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch, the composition comprising nicotine and at least one particulate non-tobacco material; andat least one capsule contained within the cavity of the water-permeable fabric pouch, the at least one capsule having a capsule wall surrounding an inner payload comprising at least one botanical.2. The pouched product of claim 1 , wherein the capsule wall comprises a material configured to be broken by shear forces.3. The pouched product of claim 1 , wherein the at least one particulate non-tobacco material comprises microcrystalline cellulose.4. The pouched product of claim 1 , wherein the nicotine is synthetic nicotine.5. The pouched product of claim 4 , wherein the synthetic nicotine is in the form of S(−)-nicotine or a racemic mixture composed predominantly of S(−)-nicotine.6. The pouched product of claim 1 , ...

Kind of Chinese medicine and microcapsule preparation method suitable for nasopharyngeal carcinoma tumor inhibitor

The invention relates to the technical field of traditional Chinese medicine, and discloses a method of traditional Chinese medicine and microcapsule preparation suitable for nasopharyngeal cancer tumor inhibitors. A traditional Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors, including: Hedyotis Diffusa, Scutellaria Barbata, Arrowshaped Tinospora Root, Rehmanniae Radix Preparata, Radix Curcumae, Crotonis Fructus, Leonurus Artemisia, Ramulus Cinnamomi, Forsythiae Fructus, Taraxacum, Radix Platycodonis and White Vinegar. Among them, the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa, 30 grams of Scutellaria Barbata, 9-12 grams of Arrowshaped Tinospora Root, 18 grams of Rehmanniae Radix Preparata, 19 grams of Radix Curcumae, 7.5 grams of Crotonis Fructus, 10 grams of Leonurus Artemisia, 7-10 grams of Ramulus Cinnamomi, 10 grams of Forsythiae Fructus, 15-30 grams of Taraxacum, 10 g of Radix Platycodonis, and 30 ml of White Vinegar. 1. A Chinese medicine suitable for nasopharyngeal cancer tumor inhibitors , which is characterized in that it comprises: Hedyotis Diffusa , Scutellaria Barbata , Arrowshaped Tinospora Root , Rehmanniae Radix Preparata , Radix Curcumae , Crotonis Fructus , Leonurus Artemisia , Ramulus Cinnamomi , Forsythiae Fructus , Taraxacum , Radix Platycodonis and White Vinegaris and White Vinegar. Among them , the raw materials for the weight ratio are as follows: 60 grams of Hedyotis Diffusa , 30 grams of Scutellaria Barbata , 9-12 grams of Arrowshaped Tinospora Root , 18 grams of Rehmanniae Radix Preparata , 19 grams of Radix Curcumae , 7.5 grams of Crotonis Fructus , 10 grams of Leonurus Artemisia , 7-10 grams of Ramulus Cinnamomi , 10 grams of Forsythiae Fructus , 15-30 grams of Taraxacum , 10 g of Radix Platycodonis , and 30 ml of White Vinegar.2. A preparation method of traditional Chinese medicine microcapsules suitable for nasopharyngeal cancer tumor inhibitors is characterized in that it ...

ANTI-ACHING SUPPLEMENT

A composition of phyto-medicaments comprising essentially of , turmeric and for the treatment necessary to alleviate ailments associated therewith. 2. The composition of claim 1 , wherein the formulation is available as a paste or emulsion.3. The composition of claim 1 , further comprising between about 4 and 12 ounces of ginger.4. The composition of claim 1 , further comprising about 1 teaspoonful of Ceylon Cinnamon.5. The composition of claim 1 , wherein adjuvants selected from the group consisting ginger claim 1 , Ceylon Cinnamon claim 1 , honey or a combination thereof.6. The composition of claim 1 , wherein water is added to texture. People who suffer from chronic pains, nagging health issues such as stress and depression, addictions, inflammation and matters of immune health can attest to the challenges and desperation in getting or obtaining treatment for their ailments without the rigor of suffering with adverse effects of the medicaments that they have to take. It is also an issue of concern that almost all the medicament taken or consumed by these patients present yet again foreign material or abstracts into them. One can presently imagine taking opioids for pain and suffering from diarrhea as an outcome, or becoming addicted to the opioids, just as examples.In other instances, nutraceuticals and other pharmaceuticals may present medicaments that come with issues of potency and sourcing. Potency, in that nutraceuticals may come from sources that may affect the efficacy of the medicament and quality of the raw materials used. Biologics offer some solutions to sufferers and there is recognition that biologics may provide challenges because of the process and the additives that make them usable for their intended purpose or purposes.Drugs, and other non-homeopathic formulations or similarly fabricated medicines used to treat issues of anti-inflammation, agues or weight management, among others are typically tied to some adverse effects of such treatment. It ...

COMPOUND FOR TREATING OXIDATIVE STRESS IN MAMMALS

Managing and treating elevated OS biomarkers in mammals such as companion animals with at least one of the supplements alpha-lipoic acid, carnitine, co-enzyme Q-10, ginger, green tea, licorice, milk thistle, garlic, honey. resveratrol, soybeans, tomatoes, turmeric, vitamin D, vitamin E or selenium. Diagnosing an oxidative stress (OS) in a mammal comprises collecting a sample; screening the sample to detect the presence of an OS biomarker, selectively isoprostane and other antioxidants such as HODE microRNAs. TAC: GSH, MDA, and TNF-alpha. The sample can be saliva. 1. A method of using a composition to reduce an isoprostane marker indicative of oxidative stress (OS) in a dog , the composition being a combination at least vitamin D and selenium ingredients alpha-lipoic acid , co-enzyme Q-10 , green tea , and turmeric , the ingredients being mixed together in powdered form and mixed into the food and being for ingestion by the dog together with food , including the screening a saliva sample of a dog to detect a level of at least an OS isoprostane biomarker; detecting the presence of the OS isoprostane biomarker based on a quantitative level of the OS isoprostane biomarker , diagnosing the degree of OS in the dog based on an increased quantitative level of the OS isoprostane biomarker , and treating a dog with a diagnosed level above 1.75 ng/ml of the OS isoprostane biomarker with the combination composition to lower the level below 1.75 ng/ml wherein the isoprostane biomarker in the dog so treated by the composition combination is reduced.2. The method for treating oxidative stress (OS) as claimed in including treating an elevated HODE OS biomarker in the dog.3. The method for treating oxidative stress (OS) as claimed in including in the combination at least two supplements selected from the group consisting of ginger claim 2 , licorice and garlic.4. The method for treating oxidative stress (OS) as claimed in including in the combination ginger claim 2 , licorice and ...

METHODS AND PRODUCTS TO PROVIDE ORAL NUTRITIONAL CARE TO SUBJECTS WITH DEMENTIA

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification. 1. A product comprising a reversibly closed container and a soup , wherein the soup is in the container and comprises:a. a total volume of 200 to 2000 ml;b. at least one of a vegetable component and a meat component;c. 300 to 2500 calories; i. 20% to 80% fat;', 'ii. 10% to 45% protein; and', 'iii. 10% to 65% carbohydrate; and', 'iv. about 2% to about 40% medium chain triglycerides,, 'd. a macronutrient caloric distribution comprisinge. optionally one or more antioxidants in a total amount of at least 100 mg equivalents of vitamin C by FRSA;f. optionally omega 3 fatty acids in an amount of at least 100 mg; andg. optionally a means for extending the stability of the product.2. The product of comprising omega 3 fatty acids in an amount of 100 to 2000 mg claim 1 , and comprising antioxidants in a total amount of 100 mg to 500 mg equivalents of vitamin C by FRSA.3. The product of wherein the product claim 1 , when provided daily to a subject with ...

METHOD FOR PRODUCING A TISSUE PAPER SHEET MATERIAL CONTAINING AN ADJUVANT SUBSTANCE FOR THE TREATMENT OF ALLERGIC RHINITIS, AND THE PRODUCT OBTAINED

The following steps are provided for producing a sheet cellulose material, for instance a handkerchief, comprising at least one adjuvant substance for the treatment of allergic rhinitis: 1. A method for producing a cellulose sheet material having a cellulose fiber-based structure and comprising at least one adjuvant substance for the treatment of allergic rhinitis , said method comprising the steps of:forming a mixture of the at least one adjuvant substance for the treatment of allergic rhinitis with at least one non-ionic surface-active agent;mixing the mixture of non-ionic surface-active agent and the at least one adjuvant substance for the treatment of allergic rhinitis in an aqueous solution of a cationic surface-active agent forming an aqueous nano- or micro-emulsion containing nano- or micro-droplet of the at least one substance encapsulated in a protective layer comprising a non-ionic surface-active agent;applying said nano- or micro-emulsion to the cellulose material;evaporating water, leading to the formation of nano- or micro-capsules anchored to the cellulose fibers.2. Method according to claim 1 , wherein said at least one adjuvant substance for the treatment of allergic rhinitis is a substance of plant origin claim 1 , preferably an essential oil.3. Method according to claim 1 , wherein said at least one adjuvant substance for the treatment of allergic rhinitis comprises at least two essential oils claim 1 , at least one of which is an adjuvant for the treatment of allergic rhinitis.4Cardiospermum HalicacabumEchium PlantagineumMelaleuca AlternifoliaEugenia CaryophyllataCupressus SempervirensOriganum MajoranaPinus SylvestrisHelianthus AnnuusHyssopus officinalisArtemisia. Method according to claim 1 , wherein the adjuvant substance for the treatment of allergic rhinitis contains at least one and preferably two essential oils selected from the group comprising: essential oil claim 1 , seed extract claim 1 , essential oil claim 1 , Ginger essential oil ...

NOVEL AND SYNERGISTIC COMPOSITION OF LECITHIN AND LYSOLECITHIN FOR IMPROVING BIOAVAILABILITY AND SOLUBILITY OF HYDROPHOBIC COMPOUNDS AND EXTRACTS

The present invention discloses a composition(s) of hydrophobic plant molecule(s) and/or extract(s) with enhanced bioavailability comprising hydrophobic active and synergetic combination of lecithin and lysolecithin and to the process for preparation thereof. 1. A composition for use in a therapeutic formulation , comprising;a synergistic mixture comprising from about 5% to about 25% of lecithin; and from about 75% to about 95% of lysolecithin, based on the combined weight of said lecithin and said lysolecithin; in combination with:a hydrophobic active ingredient.2. The composition of claim 1 , comprising:said synergistic mixture in an amount of from about 50% to about 99.99% by weight; andsaid hydrophobic active ingredient in an amount of from about 0.01 to 50% by weight; based on the combined weight of said synergistic mixture and said active ingredient.3. The composition of claim 3 , wherein:the active ingredient is at least one compound selected from the group consisting of a curcuminoid, a boswellic acid, resveratrol, hypericin, a bacoside, xanthorhizol, luteolin, Coenzyme Q10, pyrogallol, genistein, wogonin, morin, kaempferol, salts thereof, and derivatives thereof.4. The dosage form of claim 2 , wherein the active ingredient is a natural compound claim 2 , a semi-synthetic compound claim 2 , or a synthetic compound.5. A composition for use in a therapeutic formulation claim 2 , comprising;a synergistic mixture comprising from about 5% to about 25% of lecithin; and from about 75% to about 95% of lysolecithin, based on the combined weight of said lecithin and said lysolecithin; in combination with:a hydrophobic active ingredient, wherein the active ingredient is berberine, a salt thereof, or a derivative thereof.6. A composition of claim 1 , comprising;said synergistic mixture comprising from about 5% to about 25% of lecithin; and from about 75% to about 95% of lysolecithin, based on the combined weight of said lecithin and said lysolecithin; in combination ...

COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTION

Disclosed are compositions, devices, and methods to prevent and recover from detrimental effects of alcohol consumption, including significant undesirable symptoms of a hangover consciously felt by the alcohol consumer, as well as those that may not be consciously experienced. The present technology comprehensively targets multiple negative effects of hangovers. In one aspect, a composition includes dihydromyricetin (DHM); and N-acetyl cysteine (NAC). The composition may further include Prickly Pear Extract, Milk Thistle, Ginger Root, Vitamins B, C, and E, electrolytes, and/or sugars. 1. A composition for mitigating adverse effects of alcohol consumption by a person , comprising:dihydromyricetin (DHM);N-acetyl cysteine (NAC);prickly pear extract; andsilymarin.2. The composition of claim 1 ,wherein the composition includes between 50 wt. % to 65 wt. % of the DHM, between 15 wt. % to 25 wt. % of the NAC, between 5 wt. % to 15 wt. % of the prickly pear extract, and between 10 wt. % to 20 wt. % of the silymarin.3. The composition of claim 1 ,wherein the DHM includes an amount of at least 300 mg, the NAC includes an amount of at least 100 mg, the prickly pear extract includes an amount of at least 50 mg, and the silymarin includes an amount of at least 100 mg.4. The composition of claim 1 , further comprising one or more B vitamins selected from a group consisting of thiamine claim 1 , riboflavin claim 1 , niacin claim 1 , pantothenic acid claim 1 , pyridoxine claim 1 , pyridoxal claim 1 , biotin claim 1 , folic acid claim 1 , and cobalamin.5. The composition of claim 4 ,wherein the composition includes between 35 wt. % to 55 wt. % of the DHM, between 10 wt. % to 20 wt. % of the NAC, between 1 wt. % to 15 wt. % of the prickly pear extract, between 5 wt. % to 20 wt. % of the silymarin, and 5 wt. % to 20 wt. % of the one or more B vitamins, orwherein the DHM includes an amount of at least 300 mg, the NAC includes an amount of at least 100 mg, the prickly pear extract ...

A NOVEL SYNERGIC HERBAL FORMULATION FOR THE PREVENTION AND TREATMENT OF PRE-DIABETES, DIABETES AND OTHER INSULIN RESISTANCE CASES

The present invention relates to a novel synergic herbal formulation comprising Curcuma longa and Phylanthus emblica in precise combination along with one or more other ingredient for prevention and treatment of pre-diabetes, diabetes mellitus and other insulin resistance cases. Further the present invention provides a process for preparing the novel synergistic herbal formulation. 1. A novel synergistic herbal formulation comprising;a. 20% to 30% by w/w of Curcuma longa alcohol extract,b. 5% to 10% by w/w of Curcuma longa water extract,c. 1% to 10% by w/w of Turmerone oil,d. 20% to 50% by w/w of Phylanthus emblica juice powder,e. 20% to 50% by w/w of Phylanthus emblica extract,f. 10% to 15% by w/w of Phosphatidyl choline2. The novel synergistic herbal formulation as claimed in wherein Curcuma longa alcohol extract and water extract used in said formulation is extracted from Curcuma Longa Rhizomes and is 90% to 95% Curcuminoids.3. The novel synergistic herbal formulation as claimed in claim 1 , wherein the Curcuma longa water extract contains 30% to 50% of polysaccharides and turmerone oil contains 50% to 70% α-turmerone.4. The novel synergistic herbal formulation as claimed in claim 1 , wherein Phylanthus emblica juice powder contains 0.2 to 2% Vitamin C and 4 to 5.5% Gallic acid.5. The novel synergistic herbal formulation as claimed in claim 1 , wherein Phylanthus emblica extract contains 30 to 45% of tannins and 10 to 12% Gallic acid.6. The novel synergistic herbal formulation as claimed in claim 1 , wherein Phosphatidyl choline used in said formulation is 40% to 90% non GMO soya lecithin or sunflower lecithin.7. The novel synergistic herbal formulation as claimed in claim 1 , wherein the formulation contains chromium-1 ppm to 3 ppm which is an insulin sensitizer.8. The novel synergistic herbal formulation as claimed in claim 1 , wherein the formulation processed as a powder to formulate into capsule claim 1 , tablet claim 1 , granules claim 1 , sachets or liquid ...

ORALLY ADMINISTERED COMPOSITION FOR TREATING CYSTIC FIBROSIS, COPD, ASTHMA AND OTHER INFLAMMATORY CONDITIONS

The invention relates to a new orally administered composition, which in present embodiments is a standardized phytochemical formulation but other embodiments may contain designed molecules. This formulation is capable of suppressing inflammation in a variety of disease conditions having an underlying inflammatory component, including but not limited to cystic fibrosis, COPD, asthma, and pancreatitis. It is an objective of the invention to provide a non-toxic therapy, which exhibits anti-oxidant anti-inflammatory properties without deleterious side effects. 1. A composition for oral administration that is suitable for the treatment of an inflammatory condition in animals or humans , consisting of combinations of five or more natural and/or synthetic molecules that have anti-inflammatory and/or CFTR modulating functions wherein one or more compounds within the composition is capable of the following functions:(1) Molecule(s) demonstrated to reduce inflammation in experimental models and/or in vivo.(2) Molecule(s) demonstrated in experimental systems and/or in vivo to act as corrector(s) of CFTR.(3) Molecule(s) demonstrated in experimental systems and/or in vivo to act as potentiator(s) of CFTR.(4) Molecule(s) demonstrated in experimental systems and/or in vivo to increase levels of cyclic AMP.(5) Molecule(s) demonstrated in experimental systems and/or in vivo to act as phosphodiesterase inhibitors.2. A composition according to claim 1 , wherein the compounds are selected from the classes of molecules consisting of: proanthocyanidins claim 1 , anthocyanins claim 1 , procyanidins claim 1 , catechins claim 1 , flavones claim 1 , flavone glycosides claim 1 , flavonoids claim 1 , isoflavones claim 1 , curcuminoids claim 1 , lipoic acids claim 1 , stilbenes and stilbenoids claim 1 , terpenes and terpenoids claim 1 , diterpenes claim 1 , triterpenes claim 1 , pentacyclic tri-terpenes claim 1 , carotenoids claim 1 , rutosides claim 1 , bithiazoles claim 1 , ...

Method for preparing pharmaceutical compositions of rhizomes from alpinia galanga or alpinia conchigera having a high content of 1's-1'-acetoxychavicol acetate (aca)

The present invention relates to a method for preparing a granulate composition of rhizomes from Alpinia galanga or Alpinia conchigera having a high and stable content of 1′S-1′-acetoxychavicol acetate and low microbiological count, which is suitable for preparing orally ingestible dosage forms such as tablets or capsules.

COMPOSITIONS AND METHODS FOR COMBINATION INGREDIENT DELIVERY

Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either. 1. A composition comprising:a plurality of active pharmaceutical ingredients, wherein the plurality of pharmaceutical ingredients comprises an analgesic, anesthetic, antihistamine, antitussive, expectorant, decongestant, or demulcent, and wherein each of the active pharmaceutical ingredients provides relief for a cold, cough, or a sore throat, or a related symptom; anda plurality of botanical ingredients,wherein the plurality of active pharmaceutical ingredients and the plurality of botanical ingredients are present in a ratio by weight of about 1:32 to 1:65.2. The composition of claim 1 , wherein the plurality of active pharmaceutical ingredients and the plurality of botanical ingredients are present in a ratio by weight of about 1:64.310-. (canceled)11. The composition of claim 1 , wherein the analgesic claim 1 , anesthetic claim 1 , antihistamine claim 1 , antitussive claim 1 , expectorant claim 1 , decongestant claim 1 , or demulcent comprises acetaminophen claim 1 , ibuprofen claim 1 , ketoprofen claim 1 , aspirin claim 1 , naproxen claim 1 , benzocaine claim 1 , lidocaine claim 1 , dyclonine claim 1 , hexylresorcinol claim 1 , brompheniramine claim 1 , chlorpheniramine claim 1 , diphenhydramine claim 1 , dimenhydrinate guaifenesin claim 1 , phenylephrine claim 1 , pseudoephedrine claim 1 , glycerin claim 1 , or menthol.12. The composition of claim 1 , wherein the plurality of active pharmaceutical ingredients comprises at least three of: aspirin claim 1 , naproxen claim 1 , ibuprofen claim 1 , acetaminophen claim 1 , menthol claim 1 , benzocaine claim 1 , lidocaine claim 1 , dyclonine claim 1 , hexylresorcinol claim 1 , or ketoprofen.13. The ...

ANALGESIC COMPOSITIONS AND METHODS OF USE

The invention relates to the fields of pharmacology and medicine, and provides anesthetic compositions and methods for the treatment of pain using compositions comprising Tea tree oil and one or more additional agent. The invention relates to analgesic compositions for the treatment of pain associated with a variety of disorders or conditions, particularly oral or dental disorders or conditions such as alveolar osteitis or dental caries. 1. An anesthetic composition comprising a combination of Tea tree oil and one or more additional agent , comprising 0.1 ml to 1.0 ml of Tea tree oil.2. The anesthetic composition of claim 1 , wherein the ratio of Tea tree oil to the one or more additional agent is a 6:1 part by weight relationship.3. The composition of claim 1 , wherein the additional agent is selected from the group consisting of Ginger root oil claim 1 , Peppermint leaf oil claim 1 , Chamomile flower oil claim 1 , Olive leaf extract oil claim 1 , Grape seed oil claim 1 , Clove oil claim 1 , a flavoring syrup claim 1 , and an additional anesthetic agent.4. The composition of claim 3 , wherein the flavoring syrup is Cherry syrup.5. The composition of claim 3 , wherein the additional anesthetic agent is a topical anesthetic agent.6. The composition of claim 5 , wherein the topical anesthetic agent is selected from the group consisting of benzocaine claim 5 , lidocaine claim 5 , and tetracaine.7. The composition of claim 5 , wherein the topical anesthetic is benzocaine.8. The composition of claim 2 , comprising the Tea tree oil claim 2 , Ginger root oil claim 2 , Peppermint leaf oil claim 2 , Chamomile flower oil claim 2 , Olive leaf extract oil claim 2 , Grape seed oil claim 2 , Clove oil claim 2 , the flavoring syrup claim 2 , and an additional anesthetic agent in a ratio of about a 6:1:1:1:1:1:1:1:1 part by weight relationship.9. The composition of claim 1 , wherein the composition further comprises zinc oxide and/or water soluble poly(ethyleneglycol) (PEG).10. The ...

PHYTOCOMPLEXES EXHIBITING MULTIPLE, SYNERGISTIC ANTIOXIDANT ACTIVITIES USEFUL IN FOODS, DIETARY SUPPLEMENTS, COSMETICS AND PHARMACEUTICAL PREPARATIONS

Compositions comprising apple, grape, green tea, and olive extracts are presented herein. This synergistic formulations apple, grape, green tea, and olive extract are in amounts that provide a greater antioxidant activity or protein kinase modulating activity than provided by an equivalent amount of any one extract or a sum of the extracts. Further presented are methods of regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. Also presented are methods of making an activity enhancing composition for regulating oxidative stress, disease-associated protein kinase activity, and enhancing the therapeutic effect of a primary therapeutic agent. 1. An oxidative stress modulating composition comprising:a combination of apple, grape, green tea, and olive extract in amounts that provide a greater antioxidant activity than provided by an equivalent amount of any one extract or a sum of the extracts.2Malus pumila.. The composition of claim 1 , wherein the apple extract comprises an extract of a species3Vitis vinifera.. The composition of claim 1 , wherein the grape extract comprises an extract of a species4Camellia sinensis.. The composition of claim 1 , wherein the green tea extract comprises an extract of leaves of a species5Olea europea europaea.. The composition of claim 1 , wherein the olive extract comprises an extract of a subspecies6. The composition of claim 1 , wherein at least one of the extracts in the composition is present in a different amount than an amount of at least one of another extract.7. The composition of claim 1 , wherein the apple claim 1 , grape claim 1 , green tea claim 1 , and olive extracts are present in the composition at a weight ratio of about 1:1:1:1.8. The composition of claim 1 , wherein the apple claim 1 , grape claim 1 , green tea claim 1 , and olive extracts are present in the composition at a weight ratio of about 6:1:3:19. The composition of claim 1 ...

MERRIMIA TRIDENTATA COMPOSITIONS

A composition including a powder or extract of Merremia Tridentata mixed with a liposome carrier. The liposome carrier may be a lotion, cream or suspension. The composition may be used to treat Osteophytes of the spine, feet, hands, and knees. 1. A composition comprising Merremia Tridentata , the composition further comprising a topical carrier for an application to a surface of an animal body , wherein the carrier comprises a liposome.2. The composition of claim 1 , wherein the Merremia Tridentata is in the form of at least one of an extract and a powder.3. The composition of claim 2 , wherein the extract is an oil extract.4. The composition of claim 3 , wherein the oil extract is Prasarini oil.5. The composition of claim 4 , wherein the Prasarini oil is at a concentration in the carrier of at least about 1.25 g/ml to up to about 6.35 g/ml.6. The composition of claim 4 , wherein the Prasarini oil is further mixed with Mahanarayana oil.7. The composition of claim 6 , wherein the Parasarini oil and the Maharayana oil are at a ratio of at least about 3:1 and up to about 1:3.8. The composition of claim 4 , wherein 100 ml of the Prasarini oil comprises: Prasarini 7.778 g; Sahachara 7.778 g; Sathavari 7.78 g; Bala 7.78 g; Atmagupta 7.78 g; Asvagandha 7.78 g; Ketaki 7.78 g; Tagara 0.039g; Madana 0.039 g; Kushtha 0.039 g; Kesara 0.039 g; Mustaka 0.039 g; Tvak 0.039 g; Rasna 0.039 g; Saindhva 0.039 g; Pippalavu 0.039 g; Mamsi 0.039 g; Manjistha 0.039 g; Meda 0.039 g; Mahameda 0.039 g; Jivaka 0.039 g; Rsabha 0.039 g; Satapusha 0.039 g; Vyaghranakha 0.039 g; Sunti 0.039 g; Devahva 0.039 g; Kakoli 0.039 g; Ksirakakoli 0.039 g; Vaca 0.039 g; Bhallataka 0.039 g; Paya 10 ml; Masu 10 ml; Sukta 10 ml; and Mamsasarasa 10 ml.9. The composition of claim 1 , further comprising Turmeric.10. The composition of claim 1 , further comprising clove oil claim 1 , wintergreen oil claim 1 , and Boswelia oil.11. The composition of claim 1 , wherein the topical carrier is in the form of a cream ...

ULTRAPURE PHENOL COMPOSITIONS

A composition can include a cannabinoid and caprylic acid triglyceride. 1. A composition comprising:60 wt % to 99.99 wt % caprylic acid triglyceride.2. The composition of claim 1 , wherein composition includes 90 wt % to 99.99 wt % caprylic acid triglyceride.3. The composition of claim 1 , wherein composition includes 0.01 wt % to 40 wt % cannabidiol.4. The composition of claim 3 , wherein the cannabidiol is of at least 95% purity.5. The composition of claim 3 , wherein the cannabidiol is of at least 97% purity.6. The composition of claim 3 , wherein the cannabidiol is of at least 98% purity.7. The composition of claim 3 , wherein the cannabidiol is of at least 99% purity.8. The composition of claim 1 , further comprising a terpene claim 1 , flavonoid claim 1 , polyphenolic claim 1 , tumeric claim 1 , ginger claim 1 , lavender claim 1 , cumin claim 1 , valerian root claim 1 , chamomile claim 1 , arnica claim 1 , humulene claim 1 , white willow bark claim 1 , or cinnamon.9. A composition consisting essentially of a cannabinoid claim 1 , caprylic acid triglyceride and claim 1 , optionally claim 1 , 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 or 5 different plant based additives.10. The composition of claim 9 , wherein the weight ratio of cannabinoid to caprylic acid triglyceride is between 1:500 and 1:10.11. The composition of claim 9 , wherein the weight ratio of cannabinoid to caprylic acid triglyceride is between 1:250 and 1:20.12. The composition of claim 9 , wherein the composition has up to 5wt % of the plant based additive.13. The composition of claim 9 , wherein the plant based additive is a terpene claim 9 , flavonoid claim 9 , polyphenolic claim 9 , tumeric claim 9 , ginger claim 9 , lavender claim 9 , cumin claim 9 , valerian root claim 9 , chamomile claim 9 , arnica claim 9 , humulene claim 9 , white willow bark claim 9 , or cinnamon.14. The composition of claim 9 , wherein the cannabinoid includes one or more of cannabinol claim 9 , cannabidiol claim 9 , ...

Compositions and methods for nutritional supplements

Compositions and methods are presented in which a plurality of chemically distinct polyphenols inhibit multiple enzymes in pathways associated with health and healthy ageing. Preferred compositions are derived from colored plant materials that are commonly found in the Mediterranean diet and provide the biochemical basis for the health benefits of the Mediterranean diet. Notably, the enzyme inhibition observed with the combined polyphenols was synergistic with respect to not one but a significant number of enzymes in the pathways associated with health and healthy ageing, thus providing an amplified desirable effect.

PHYTOCOMPOSITION FOR THE TREATMENT OF PAIN RELATED TO JOINT DISEASES

It is disclosed a phytocomposition which includes: (a) 0.01 wt % to 26 wt % of extract; (b) 0.01 wt % to 26 wt % of extract; (c) 0.01 wt % to 26 wt % of extract; and (d) 0.01 wt % to 26 wt % of extract. Said phytocomposition can be used in combination with a pharmaceutically acceptable carrier in order to obtain a pharmaceutical composition that can be used for treating muscle, arthritic and rheumatic pain in a patient, caused by joint diseases, in particular rheumatoid arthritis, osteoarthritis, fibromyalgia, gouty arthritis, psoriatic arthritis, lupus and juvenile arthritis. 1. A phytocomposition comprising the following weight percentage concentrations of the total weight of the phytocomposition:{'i': 'Arnica montana;', 'a) from 0.01% to 15% of an extract of'}{'i': 'Rosmarinus officinalis;', 'b) from 0.01% to 15% of an extract of'}{'i': 'Zingiber officinale', 'c) from 0.01% to 15% of an extract of ; and'}{'i': 'Boswellia serrata.', 'd) from 0.01% to 15% of an extract of'}23.-. (canceled)4. A phytocomposition according to claim 1 , wherein the extracts are present in the phytocomposition according to the following weight percentage concentrations of the total weight of the phytocomposition{'i': 'Arnica montana;', 'a) from 8% to 12% of the extract of'}{'i': 'Rosmarinus officinalis;', 'b) from 8% to 12% of the extract of'}{'i': 'Zingiber officinale', 'c) from 8% to 12% of the extract of ; and,'}{'i': 'Boswellia serrata.', 'd) from 8% to 12% of the extract of'}5Arnica montana, Rosmarinus officinalis, Zingiber officinaleBoswellia serrata. A phytocomposition according to claim 1 , wherein the extracts of and claim 1 , are selected from the group consisting of aqueous extracts claim 1 , alcoholic extracts and hydro-alcoholic extracts.6. A phytocomposition according to claim 5 , wherein the selected extracts selected are hydro-alcoholic extracts.7. A pharmaceutical composition claim 1 , wherein it comprises a therapeutically effective amount of the phytocomposition as ...

METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER

The present invention is directed to therapeutic methods and compositions for treating non-small cell lung cancer in a subject comprising administering an effective amount of an extract or powder of a herbal mixture, optionally with an anti-cancer agent to said subject. The herbal mixture comprises a component of at least one species from each of the genus -Red, -White, -Viride, -Red, and Zingiber officinale radix. 1Astragalus, Cimicifuga foetida rhizoma, Ophiopogon radix, Atractylodes lancea rhizoma, Panax GinsengAtractylodes rhizomaMassa medicata fermentata, Citrus reticulataCitrus reticulata, Glycyrrhiza radix, Schisandra fructus, Angelica sinensis radix, Phellodendron cortex, Alisma rhizoma, Pueraria radix, Ziziphus fructusZingiber officinale radix.. A composition for treating non-small cell lung cancer in a subject comprising an extract or powder of a herbal mixture , and an anti-cancer agent , wherein said herbal mixture comprises a component of at least one species from each of the genus -Red , -White , -Viride , -Red , and2. The composition of claim 1 , wherein the anti-cancer agent is selected from the group consisting of estrogen receptor modulators claim 1 , androgen receptor modulators claim 1 , retinoid receptor modulators claim 1 , cytotoxic/cytostatic agents claim 1 , antiproliferative agents claim 1 , prenyl-protein transferase inhibitors claim 1 , HMG-CoA reductase inhibitors claim 1 , nitrogen mustards claim 1 , nitroso ureas claim 1 , angiogenesis inhibitors claim 1 , inhibitors of cell proliferation and survival signaling pathway claim 1 , apoptosis inducing agents claim 1 , agents that interfere with cell cycle checkpoints claim 1 , agents that interfere with receptor tyrosine kinases (RTKs) claim 1 , integrin blockers claim 1 , NSAIDs claim 1 , PPAR agonists claim 1 , inhibitors of inherent multidrug resistance (MDR) claim 1 , anti-emetic agents claim 1 , agents useful in the treatment of anemia claim 1 , agents useful in the treatment of ...

NUTRACEUTICAL SUPPLEMENT WITH LACTOBACILLUS RHAMNOSUS

Compositions and uses thereof include an admixture of a probiotic and natural phytochemicals that can affect an individual's stem cells and the inflammatory process to reduce underlying symptoms of various health issues, including arthritis, aging, and physical or athletic injuries, thereby facilitating healing and repair of tissues. 1. A dietary supplement , comprising a composition including a synergistic combination of:{'i': 'Lactobacillus rhamnosus;'}ginger; andvitamin D.2Lactobacillus rhamnosusLactobacillus rhamnosus.. The dietary supplement of claim 1 , wherein the comprises about 10 billion CFU of3. The dietary supplement of claim 1 , wherein the ginger comprises about 500 mg ginger.4. The dietary supplement of claim 1 , wherein the vitamin D comprises about 1 claim 1 ,000 IU of vitamin D.5. The dietary supplement of claim 1 , further comprising curcumin.6. The dietary supplement of claim 6 , wherein the curcumin comprises about 350 mg tumeric root extract.7Boswellia. The dietary supplement of claim 1 , further comprising extract.8BoswelliaBoswellia serrata. The dietary supplement of claim 7 , wherein the extract comprises about 500 mg extract.9Boswellia. The dietary supplement of claim 1 , further comprising curcumin and extract.10. The dietary supplement of claim 1 , further comprising green tea extract.11Camellia sinensis. The dietary supplement of claim 10 , wherein the green tea extract comprises about 500 mg of green tea leaf extract of standardized to about 98% polyphenols claim 10 , 80% catechins claim 10 , and 50% epigallocatechin gallate.12Boswellia. The dietary supplement of claim 1 , further comprising extract and green tea extract.13Epidmedium. The dietary supplement of claim 1 , further comprising extract.14EpidmediumEpimedium sagittatum. The dietary supplement of claim 13 , wherein the extract comprises about 500 mg of extract standardized to about 10% icariin.15Epimedium. The dietary supplement of claim 1 , further comprising curcumin and ...

Edible Product

The present invention describes an orally administered edible product designed to provide a health benefit in a delivery formulation that will increase ease of use and thus lead to increased compliance and consumption to promote human health and wellness. 1. An edible product comprised of a mixture containing: (1) at least one plant-based product and (2) at least one lipid-based edible substance wherein said mixture is fully or partially enclosed in an edible coating.2. The edible product of claim 1 , wherein said edible product is intended to have a therapeutic claim 1 , curative or preventative health benefit.3. The health benefit of claim 2 , wherein said health benefit includes prevention or treatment of at least one disease or physical disorder selected from the group comprised of claim 2 , but not limited to: inflammatory diseases claim 2 , cardiovascular diseases claim 2 , metabolic diseases claim 2 , autoimmune diseases claim 2 , bone and joint diseases claim 2 , central nervous system diseases and endocrine disorders.4. The plant-based product of claim 1 , wherein said plant based product can be a crude preparation claim 1 , paste claim 1 , powder or extract selected from the group comprised of claim 1 , but not limited to: the leaves claim 1 , roots claim 1 , stem claim 1 , seeds claim 1 , fruits claim 1 , flowers claim 1 , bark claim 1 , nuts claim 1 , tubers claim 1 , tumors claim 1 , other potentially edible components of a plant or tree claim 1 , and mixtures thereof.5. The extract of wherein said extract is comprised of selected active ingredients of said plant-based product.6. The plant-based product of claim 1 , wherein said plant-based product is selected from the group comprised of claim 1 , but not limited to claim 1 , plant-derived products described in: Western herbal preparations claim 1 , naturopathic medicine claim 1 , Ayurveda claim 1 , Unani medicine claim 1 , Siddhi medicine claim 1 , other systems of alternative plant based medicine ...

NITRITE COMPOSITIONS AND USES THEREOF

The present invention relates to compositions of nitrite and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition of inorganic nitrite, or a pharmaceutically acceptable salt thereof, for supplementation in subjects with diabetes, peripheral artery diseases or in patients with risk factors associated with cardiovascular diseases. 1. A dietary supplement comprising one or more fruit or herbal extracts and at least 5% by weight of a nitrite salt.2. The dietary supplement of claim 1 , wherein the extract is an herbal extract selected form the group consisting of gingko biloba claim 1 , garlic claim 1 , ginger claim 1 , pepper claim 1 , parsley claim 1 , orange claim 1 , yohimbine claim 1 , astragalus claim 1 , catuaba claim 1 , schisandra claim 1 , and sulforaphane.3. The dietary supplement of claim 2 , wherein the herbal extract is a mixture of gingko biloba and garlic or wherein the herbal extract is gingko biloba.4. (canceled)5. The dietary supplement of formulated for steady-state release over a period of about 2 hours to about 24 hours; formulated for daily administration; or formulated for oral administration.67-. (canceled)8. The dietary supplement of claim 1 , wherein the nitrite salt is sodium nitrite claim 1 , potassium nitrite claim 1 , or calcium nitrite.9. The dietary supplement of in the form of a tablet or capsule.10. A method for increasing nitrite levels in a person having a nitrite nutritional deficiency claim 1 , the method comprising administering to the person a supplement of in a dosing regimen sufficient to alleviate the nutritional deficit.11. The method of claim 10 , wherein the dosing regimen administered to a subject results in a plasma level of nitrite of about 0.05 to 0.6 μM; wherein a unit dose of about 0.5 μg/kg to about 1000 μg/kg is administered; or wherein said nitrite nutritional deficiency is a result of dietary ...

PREBIOTIC MIXTURE

The present invention refers to a prebiotic mixture comprising at least one plant polysaccharide fibre and at least one of Propolis and/or and/or extracts, optionally comprising also and/or extracts. Moreover, the present invention also relates to said mixture for use in the preservation and/or in the restoration of the intestinal microbiota balance. 1Olea europaeaAloe veraThymus vulgarisAgrimonia eupatoria. A prebiotic mixture comprising at least one plant polysaccharide fibre and one of and/or Propolis and/or extracts and one of and/or extracts.2Linum usitatissimum. The prebiotic mixture according to claim 1 , wherein said at least one plant polysaccharide fibre is selected from the group consisting of inulin claim 1 , mucilages of Malvaceaes claim 1 , flea-worth fibres claim 1 , mucilages from claim 1 , glucomannan fibres claim 1 , spear grass fibres claim 1 , and gum arabic.3Cichorium intybusHelianthus tuberosusCynara scolymusTaraxacum officinalisArctium lappa.. The prebiotic mixture according to claim 2 , wherein said inulin is extracted from and/or and/or and/or and/or4Malva silvestrisAlthaea officinalis.. The prebiotic mixture according to claim 2 , wherein said mucilages of Malvaceaes are mucilages from and/or mucilages from5Plantago psyliumPlantago indicaPlantago ovata.. The prebiotic mixture according to claim 2 , wherein said flea-worth fibres are fibres from seeds or cuticle of and/or and/or6Amorphophallus konjac. The prebiotic mixture according to claim 2 , wherein said glucomannan fibres are fibres from tuber.7Cynodon dactylonElymus repens.. The prebiotic mixture according to claim 2 , wherein said spear grass fibres are fibres from rhizome of and/or8Althaea officinalisThymus vulgarisOlea europaea. The prebiotic mixture according to comprising inulin claim 7 , mucilages from claim 7 , gum arabic claim 7 , a extract claim 7 , a Propolis extract claim 7 , and an extract.9Althaea officinalisOlea europaeaThymus vulgarisAgrimonia eupatoria. The prebiotic ...

ANALGESICS BASED ON SNAKE VENOMS

A homeopathic pain topical analgesic composition based on snake venom is disclosed. The study product also contained of a homeopathic remedy most frequently used for fractures, bruises, and muscle strains due to its analgesic and anti-inflammatory effects. The composition also contained a penetrant component to enhance penetration of the ingredients as well as an analgesic/anti-inflammatory component. The snake venoms used may include those of and A clinical study of a product formulated in this way was effective in promoting relief from muscle pain and discomfort. 1. A topical analgesic composition comprising: water;', 'methocel;', 'glucono-delta-lactone; and', 'benzalkonium chloride;, 'an aqueous preservation vehicle comprising [{'i': 'Naja naja', 'venom; and'}, {'i': 'Crotalus horridus', 'venom;'}], 'a venom component comprisingan analgesic/anti-inflammatory component; anda penetrant component comprising propylene glycol.2. The topical analgesic composition of claim 1 , wherein the analgesic/anti-inflammatory component comprises:{'i': 'Capsicum;'}{'i': 'Boswellia', 'extract;'}{'i': 'Arnica Montana;', 'and'}{'i': 'Curcuma longata.'}3. The topical analgesic composition of claim 1 , wherein the analgesic/anti-inflammatory component comprises:{'i': 'Populus tremula;'}{'i': 'Fraxinus excelsior;', 'and'}{'i': 'Solidago virgaurea.'}4. The topical analgesic composition of claim 1 , wherein the penetrant component further comprises oleic acid and isopropyl alcohol.5. The topical analgesic composition of claim 1 , wherein the penetrant component further comprises menthyl lactate.6. The topical analgesic composition of claim 1 , wherein the penetrant component further comprises linalool.7. The topical analgesic composition of claim 1 , wherein the penetrant component further comprises MSM.8Lachesis muta. The topical analgesic composition of claim 1 , wherein the venom component further comprises venom.9. A topical analgesic composition comprising: water;', 'methocel;', ' ...

Development of curcumin and piperine loaded double-layered biopolymer based nano delivery systems by using electrospray / coating method

A double-layered particle having a core layer formed of zein protein, in which the active agent curcumin and/or its derivatives are encapsulated, and an outer shell layer formed of chitosan and/or its derivatives, in which the active agent piperine is encapsulated, and which is coated over the core layer.

MALE AND FEMALE INFERTILITY HERBAL COMPOSITION

An herbal composition that enhances and promotes fertility in both males and females by nourishing the kidney, regulating the liver and spleen, improving circulation of Qi and blood, and balancing the Yin and Yang through a unique composition consisting of natural herbs known in traditional Chinese medicine. The herbs create a synergy between each other that works to enhance fertility for both males and females. The composition consists of the following herbal ingredients mixed in varying weight percentages. goji berry, dodder seed, red sage root, green orange peel, processed fleece flower root, horny goat weed, codonopsis, raspberry, astragalus root, Chinese yam, white peony root, false daisy, mulberry, curcuma tuber, and cynomorium. The herbal ingredients are cleaned, purified and/or processed prior to formulation. The formulation process is at least partially dependent on the desired means of preparation and administering the composition. 1. An herbal composition for enhancing fertility in males and females , the composition comprising:about 3 to 15 weight percent Fructus Lycii, about 3 to 15 weight percent Semen Cuscutae, about 3 to 10 weight percent Radix Salviae Miltiorrhizae, about 1 to 5 weight percent Pericarpium Citri Reticulatae Viride preparata, about 3 to 15 weight percent Radix Polygoni Multiflori preparata, about 3 to 10 weight percent Herba Epimedii, about 3 to 15 weight percent Radix Codonopsis, about 3 to 15 weight percent Fructus Rubi, about 3 to 10 weight percent Radix Astragali, about 3 to 10 weight percent Rhizoma Dioscoreae, about 3 to 10 weight percent Radix Paeoniae Alba, about 3 to 10 weight percent Herba Ecliptae, about 5 to 10 weight percent Fructus Mori, about 3 to 10 weight percent Radix Curcumae, and about 3 to 10 weight percent Herba Cynomorii.2. The composition of claim 1 , wherein the composition is administered in at least one of the following ways: oral claim 1 , topical claim 1 , suppository claim 1 , intravenous claim 1 , ...

A POLYHERBAL COMPOSITION FOR IDIOPATHIC PULMONARY FIBROSIS (IPF)

The present disclosure envisages a polyherbal composition comprising the extracts of and for alleviating the symptoms and reduces the clinical progression of Idiopathic pulmonary fibrosis (IPF). Further, the composition comprises at least one pharmaceutically acceptable excipient selected from the group consisting of microcrystalline cellulose, modified starch and maltodextrin. The present disclosure also envisages a process for preparing the poly-herbal composition for alleviating the symptoms of Idiopathic pulmonary fibrosis (IPF). 1. (canceled)2. A polyherbal composition comprising:{'i': 'Curcuma longa', 'i) extract of in an amount ranging from 10 wt % to 70 wt % of the total weight of the composition;'}{'i': 'Camellia sinensis', 'ii) extract of in an amount ranging from 20 wt % to 40 wt % of the total weight of the composition; and'}{'i': 'Phyllanthus emblica', 'iii) extract of in an amount ranging from 1 wt % to 20 wt % of the total weight of the composition.'}3. The polyherbal composition as claimed in claim 2 , further comprises at least one pharmaceutically acceptable excipient selected from the group consisting of microcrystalline cellulose claim 2 , modified starch and maltodextrin in an amount ranging from 5 wt % to 10 wt % of the total weight of the composition.4. The polyherbal composition of claim 2 , further comprising:{'i': 'Curcuma longa', 'extract of in an amount ranging from 30 wt % to 60 wt % of the total weight of the composition.'}5. A process for preparing a polyherbal composition comprising:{'i': Curcuma longa,', 'Camellia sinensis', 'Phyllanthus emblica, 'predetermined amounts of the extract of extract of and extract of are mixed in a reaction vessel to form a homogenised mixture; and'} 'wherein said pharmaceutically acceptable excipients are selected from the group consisting of microcrystalline cellulose, modified starch and maltodextrin.', 'adding at least one pharmaceutically acceptable excipients to the homogenized mixture followed by ...

Methods of Making and Using Polyphenols Complexed With a Protein, Peptide, Amino Acid, Polysaccharide, Disaccharide, or Monosaccharide

The present invention a polyphenol complexes with amino acids, peptides, proteins, glycosaminoglycans, polysaccharides, mucopolysaccharide, disaccharides, monosaccharides, amino sugars, glycol-proteins, DNA/RNA oligonucleotides, mRNA, siRNA, antibodiesor other micro- or macro biomolecules. 1. A polyphenol complex comprising:a therapeutically effective amount of one or more polyphenols selected from a turmeric extract, a curcumin, a curcuminoid, a grapeseed extract, a resveratrol, a milk thistle extract, a silymarin, a silibinin, a green tea extract, a epigallocatechin gallate and a quercetin; andone or more complexing agents conjugated to a therapeutically effective amount of one or more polyphenols, wherein the one or more complexing agents are selected from proteins, peptides, amino acids, polysaccharides, disaccharides, monosaccharides, amino sugars, glycosaminoglycans, and glycol-proteins, disposed in a pharmaceutically acceptable excipient, diluent, or carrier.2. The composition of claim 1 , wherein the therapeutically effective amount of one or more polyphenols are non-covalently conjugated to the complexing agent.3. The composition of claim 1 , wherein the therapeutically effective amount of one or more polyphenols comprise 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , or more polyphenols.4. The composition of claim 1 , wherein the proteins are selected from Whey protein isolate claim 1 , Egg protein isolate claim 1 , Oat protein isolate claim 1 , Hemp protein claim 1 , Sunflower protein isolate Pea protein isolate claim 1 , soybean protein isolate claim 1 , fishmeal claim 1 , flaxseed and Brown rice protein isolate.5. The composition of claim 1 , wherein the one or more complexing agents comprise N-acetylglucosamine claim 1 , glucosamine sulfate or N-acetylgalactosamine claim 1 , glucuronic acid claim 1 , iduronic acid claim 1 , galactose chondroitin and glucosamine claim 1 , glycosaminoglycan Chondroitin sulfate or Glucosamine sulfate.6. The ...

QUALITY OF LIFE EXTENSION THERAPIES RELATING TO AGING, FOOD ALLERGIES, PAIN AND REDUCED VIGOR BY MANAGING MOLECULAR, CELLULAR AND SUBCELLULAR BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OTHER ORGANELLE PROCESSES

This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its ...

COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTION

Disclosed are compositions, devices, and methods to prevent and recover from detrimental effects of alcohol consumption, including significant undesirable symptoms of a hangover consciously felt by the alcohol consumer, as well as those that may not be consciously experienced. The present technology comprehensively targets multiple negative effects of hangovers. In one aspect, a composition includes dihydromyricetin (DHM); and N-acetyl cysteine (NAC). The composition may further include Prickly Pear Extract, Milk Thistle, Ginger Root, Vitamins B, C, and E, electrolytes, and/or sugars. 1. A composition for mitigating adverse effects of alcohol consumption by a person , comprising:dihydromyricetin (DHM);N-acetyl cysteine (NAC);prickly pear extract; andsilymarin.25.-. (canceled)6. The composition of claim 1 ,wherein the composition includes between 50 wt. % to 65 wt. % of the DHM, between 15 wt. % to 25 wt. % of the NAC, between 5 wt. % to 15 wt. % of the prickly pear extract, and between 10 wt. % to 20 wt. % of the silymarin.7. The composition of claim 1 ,wherein the DHM includes an amount of at least 300 mg, the NAC includes an amount of at least 100 mg, the prickly pear extract includes an amount of at least 50 mg, and the silymarin includes an amount of at least 100 mg.8. (canceled)9. The composition of claim 1 , further comprising one or more B vitamins selected from a group consisting of thiamine claim 1 , riboflavin claim 1 , niacin claim 1 , pantothenic acid claim 1 , pyridoxine claim 1 , pyridoxal claim 1 , biotin claim 1 , folic acid claim 1 , and cobalamin.10. The composition of claim 9 ,wherein the composition includes between 35 wt. % to 55 wt. % of the DHM, between 10 wt. % to 20 wt. % of the NAC, between 1 wt. % to 15 wt. % of the prickly pear extract, between 5 wt. % to 20 wt. % of the silymarin, and 5 wt. % to 20 wt. % of the one or more B vitamins, orwherein the DHM includes an amount of at least 300 mg, the NAC includes an amount of at least 100 mg, ...

Herbal composition for the treatment and management of cancer and method of preparation thereof

Herbal composition for the treatment and management of cancer and method of preparation are disclosed herein. The disclosed composition includes a combination of herb and mineral components that facilitate in inhibiting abnormal cell proliferation. The embodiments of the composition can thus be used in treatment of cancer and related morbidities. Also, disclosed herein is a method for inducing cytotoxicity in cancer cells. 1Vinca rosea, Aristolochia indica, Eclipta alba, Moringa oleifera, Curcuma longaor. A composition for the treatment and management of cancer comprising extracts thereof; and a therapeutically effective amount of Kajjali.2Vinca rosea. The composition for the treatment and management of cancer as claimed in claim 1 , wherein claim 1 , is present in an amount ranging from 3 to 6 wt % of the total weight of the composition.3Aristolochia indica. The composition for the treatment and management of cancer as claimed in claim 1 , wherein is present in an amount ranging from 3 to 6 wt % of the total weight of the composition.4Eclipta alba. The composition for the treatment and management of cancer as claimed in claim 1 , wherein is present in an amount ranging from 3 to 6 wt % of the total weight of the composition.5Moringa oleifera. The composition for the treatment and management of cancer as claimed in claim 1 , wherein is present in an amount ranging from 3 to 6 wt % of the total weight of the composition.6Curcuma longa. The composition for the treatment and management of cancer as claimed in claim 1 , wherein is present in an amount ranging from 3 to 6 wt % of the total weight of the composition.7. The composition for the treatment and management of cancer as claimed in claim 1 , wherein Kajjali is present in an amount ranging from 0.1 to 20 wt % of the total weight of the composition.8Boerhavia diffusa, Adhatoda vasica, Bauhinia variegate, Commiphora mukul, Azadirachta indica, Aconitum heterophyllum, Smilax china, Tinospora cordifolia, Withania ...

Composition of Plant Extracts That Increase Döderlein's Bacilli, Used for the Treatment of Sexually Transmitted Diseases (STD) and the Human Papillomavirus (HPV), Having an Aphrodisiac Effect

The present invention relates to a composition made from extracts of ginger (Zingiber officinale), clove (Syzygium aromaticum), green tea (Camellia sinensis), pot marigold (Calendula officinalis), broccoli (Brassica oleracea italica) and garlic (Allium sativum), suitable for use in the prevention and treatment of HPV and sexually transmitted diseases (STD). The composition increases Döderlein's bacilli, as well as additionally facilitating orgasm in women.

A phytochemical composition for sickle cell anemia treatment

A phytochemical composition for treatment of sickle cell anemia has been developed. The composition is a solid mixture of inorganic salts and various organic compounds of herbal origin and obtained by extracting a mixture of five herbs namely Piper guineenses seeds, Pterocarpus osum stem, Eugenia carophyllum fruit, Sorghum bicolor leaves and Curcuma longa tuber with aquous solution of sodium/potassium bicarbonate and sodium/potassium carbonate and then concentrating the extract to obtain a powder. Also described are methods of preparation of extraction product and method of its use for treatment of sickle cell disease afflicted patients.

DETOXIFYING COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING SAME

A detoxifying composition for oral administration includes dried inflorescence stems from the pepper plant, that are optionally ground and optionally sieved, and/or a liquid or dry extract of pepper plant inflorescence stems. The pepper plant inflorescence stems are advantageously chosen from inflorescence stems from the , or pepper plants. The food composition or supplement or fortified foodstuff or dietary product containing same is used in order to promote the elimination of waste from the organism, in particular by the liver. 1. A detoxifying composition for oral administration , wherein said detoxifying composition comprises dried , optionally ground and optionally screened pepper plant inflorescence stems and/or a liquid or dry extract of pepper plant inflorescence stems.2Piper nigrumPiper longum.. The composition as claimed in claim 1 , wherein the pepper plant inflorescence stems are chosen from the inflorescence stems of the pepper plant or3. The composition as claimed in either of claim 1 , wherein the extract is an extract of said inflorescence stems with a polar solvent.4. The composition as claimed in claim 1 , wherein said composition contains at least 1% by weight.5. The composition as claimed in claim 1 , wherein said composition is in a drinkable form claim 1 , such as in the form of an infusion claim 1 , a decoction claim 1 , a maceration claim 1 , a flavored drink or any other drinkable form.6. A food supplement or a fortified food or a dietetic product comprising the composition as claimed in claim 1 , in weight proportions of between 0.1% and 85%.7. The food supplement or fortified food or dietetic product as claimed in claim 6 , wherein said food supplement also comprises at least one active agent chosen from: vitamins claim 6 , such as vitamin B6 or C; carotenoids claim 6 , such as beta-carotene or lutein; mineral trace elements claim 6 , such as magnesium claim 6 , calcium or iron; or extracts of rosemary claim 6 , blessed milkthistle claim 6 ...

Combined herbal and pharmaceutical composition and method

An herbal combination composition can include, herbal extracts, including combinations of: , and ; pharmaceutical compositions, including combinations of: Brompheniramine Maleate, Pseudoephedrine, dextromethorphan, guaifenesin, acetaminophen, phenylephrine, diphenhydramine. The herbal combination composition can further include: polyethylene glycol; propylene glycol; poloxamer 407; ethylenediaminetetraacetic acid; methyl paraben; potassium sorbate; propyl paraben; xanthan gum; sodium citrate, citric acid; anhydrous citric acid; and purified acetate buffered water. Also disclosed is a method for manufacture of an herbal combination composition, including dissolving herbal extracts, adding poloxamer, adding pharmaceutical compositions, adding acetate buffer, adding xanthan gum gel, adding acetate buffer. 1. An herbal combination composition , comprising: [{'i': 'Viola odorata;'}, {'i': 'Chamomile', '; and'}, {'i': 'Ocimum tenuiflorum', '; and'}], 'a) an herbal extract combination, comprising Guaifenesin in a range of 200-1200 mg; and', 'Dextromethorphan in a range of a 5-80 mg., 'b) a pharmaceutical combination composition, comprising2. The herbal combination composition of claim 1 , wherein the pharmaceutical combination composition further comprises:Brompheniramine maleate in a range of 1 to 12 mg.3. The herbal combination composition of claim 1 , wherein the pharmaceutical combination composition further comprises:Pseudoephedrine in a range of 15-120 mg.4. The herbal combination composition of claim 1 , wherein the herbal extract combination further comprises:{'i': 'Centella asiatica.'}5. The herbal combination composition of claim 4 , wherein the herbal extract combination comprises:{'i': 'Centella asiatica', 'a) the in a range of 0.25% to 1.5% by weight of the herbal combination composition;'}{'i': 'Viola odorata', 'b) the in a range of 0.25%-1.5% by weight of the herbal combination composition;'}{'i': 'Chamomile', 'c) the in a range of 0.25% to 1.0% by weight of ...

CANNABINOID AND CBD LIPOSOME FORMULATIONS AND USES THEREOF

Aspects of the present application provide liposomal formulations of cannabinoid extracts. Method of using such formulation, e.g., for the treatment of inflammation are also provided. 1. A composition comprising a liposomal formulation of a cannabinoid extract;wherein said composition is formulated in a nutraceutical or pharmaceutical formulation; formulated for oral, sublingual, ocular or topical administration;wherein said liposomal formulation is dissolved in a substantially aqueous carrier; andwherein the liposomal formulation comprises a phospholipid, and further wherein the phospholipid comprises at least 70% of one or more phosphocholine sources;wherein said cannabinoid extract is composed of at least about 95% cannabidiol by weight, andwherein said cannabinoid extract is essentially free from tetrahydrocannabinol (THC) components.2. The composition of claim 1 , wherein the cannabinoid extract further comprises cannabigerol (CBG) claim 1 , cannabidivarin (CBDV) claim 1 , Cannabinol (CBN) and/or cannabichromene (CBC).3. The composition of claim 1 , wherein the cannabinoid extract is composed of at least about 96% claim 1 , 97% claim 1 , 98% or 99% cannabidiol by weight.4. The composition of claim 1 , wherein the cannabinoid extract further comprises less than 1% (CBG) claim 1 , (CBDV) claim 1 , (CBN) and/or cannabichromene (CBC) by weight.5. The composition of claim 1 , wherein the phospholipid is phosphocholine (PC) claim 1 , egg PC claim 1 , soybean PC claim 1 , DPPC or DOPC.6. The composition of claim 1 , wherein the liposomes of the liposomal formulation are composed of at least 75% claim 1 , 80% or 85% PC.7. The composition of claim 1 , wherein the liposomes comprise a cholesterol component.8. The composition of claim 1 , wherein the liposomes of the liposomal formulation further comprise a protein component claim 1 , BSA and/or lithocholic acid.9. The composition of claim 1 , wherein the aqueous carrier comprises water claim 1 , fruit juice claim 1 , ...